WO2014174522A1 - Improved processes for the preparation of linezolid using novel intermediates - Google Patents
Improved processes for the preparation of linezolid using novel intermediates Download PDFInfo
- Publication number
- WO2014174522A1 WO2014174522A1 PCT/IN2013/000278 IN2013000278W WO2014174522A1 WO 2014174522 A1 WO2014174522 A1 WO 2014174522A1 IN 2013000278 W IN2013000278 W IN 2013000278W WO 2014174522 A1 WO2014174522 A1 WO 2014174522A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- mixture
- enantiomeric
- group
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 173
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims abstract description 80
- 229960003907 linezolid Drugs 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 63
- 239000000543 intermediate Substances 0.000 title abstract description 27
- -1 (R)-phthalimido-2-hydroxypropyl-carbamate compound Chemical class 0.000 claims description 259
- 239000000203 mixture Substances 0.000 claims description 177
- 239000002904 solvent Substances 0.000 claims description 151
- 238000006243 chemical reaction Methods 0.000 claims description 90
- 150000001875 compounds Chemical class 0.000 claims description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 64
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 63
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 61
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 59
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 57
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 57
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 51
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 50
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 49
- 125000001188 haloalkyl group Chemical group 0.000 claims description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 41
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 39
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 39
- 239000003153 chemical reaction reagent Substances 0.000 claims description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 38
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 36
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 35
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 33
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 32
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 32
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 31
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 31
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 31
- 125000003944 tolyl group Chemical group 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 23
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 22
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 22
- 230000003213 activating effect Effects 0.000 claims description 21
- WSSLICDKCXLDOS-LLVKDONJSA-N 3-fluoro-4-morpholin-4-yl-N-[[(2R)-oxiran-2-yl]methyl]aniline Chemical compound Fc1cc(NC[C@@H]2CO2)ccc1N1CCOCC1 WSSLICDKCXLDOS-LLVKDONJSA-N 0.000 claims description 19
- 150000007529 inorganic bases Chemical class 0.000 claims description 19
- 150000007530 organic bases Chemical class 0.000 claims description 19
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 18
- 235000011181 potassium carbonates Nutrition 0.000 claims description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 18
- 239000004215 Carbon black (E152) Substances 0.000 claims description 17
- 150000008282 halocarbons Chemical class 0.000 claims description 17
- 229930195733 hydrocarbon Natural products 0.000 claims description 17
- 150000002430 hydrocarbons Chemical class 0.000 claims description 17
- 150000002576 ketones Chemical class 0.000 claims description 17
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 16
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 16
- 239000012345 acetylating agent Substances 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 150000002825 nitriles Chemical class 0.000 claims description 16
- 239000003880 polar aprotic solvent Substances 0.000 claims description 16
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 16
- UVDYUDNYSNKZRV-OAHLLOKOSA-N (R)-2-(3-((3-Fluoro-4-morpholinophenyl)amino)-2-hydroxypropyl)isoindoline-1,3-dione Chemical compound C([C@@H](O)CN1C(C2=CC=CC=C2C1=O)=O)NC(C=C1F)=CC=C1N1CCOCC1 UVDYUDNYSNKZRV-OAHLLOKOSA-N 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 claims description 14
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 13
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 13
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 10
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 10
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 9
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 9
- 150000003141 primary amines Chemical class 0.000 claims description 9
- FXEQKPURRDLLDG-ZDUSSCGKSA-N (5S)-5-(3-fluoro-N-methyl-4-morpholin-4-ylanilino)-1,3-oxazolidin-2-one Chemical compound CN([C@@H]1CNC(=O)O1)c1ccc(N2CCOCC2)c(F)c1 FXEQKPURRDLLDG-ZDUSSCGKSA-N 0.000 claims description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 8
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 claims description 8
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 8
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 8
- 239000000920 calcium hydroxide Substances 0.000 claims description 8
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 8
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 claims description 8
- NWVJOHFMZMWYCQ-KRWDZBQOSA-N ethyl n-[(2r)-3-(1,3-dioxoisoindol-2-yl)-2-hydroxypropyl]-n-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical group C([C@H](O)CN1C(C2=CC=CC=C2C1=O)=O)N(C(=O)OCC)C(C=C1F)=CC=C1N1CCOCC1 NWVJOHFMZMWYCQ-KRWDZBQOSA-N 0.000 claims description 8
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 8
- 239000000347 magnesium hydroxide Substances 0.000 claims description 8
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 8
- 239000011736 potassium bicarbonate Substances 0.000 claims description 8
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 8
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 8
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 8
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 claims description 8
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 claims description 8
- 239000008096 xylene Substances 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 6
- SVOSGQHNQMBGRF-IBGZPJMESA-N [(2R)-1-(1,3-dioxoisoindol-2-yl)-3-(N-ethoxycarbonyl-3-fluoro-4-morpholin-4-ylanilino)propan-2-yl] acetate Chemical compound CCOC(=O)N(C[C@@H](CN1C(=O)c2ccccc2C1=O)OC(C)=O)c1ccc(N2CCOCC2)c(F)c1 SVOSGQHNQMBGRF-IBGZPJMESA-N 0.000 claims description 6
- 230000000397 acetylating effect Effects 0.000 claims description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 claims description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 5
- 239000012346 acetyl chloride Substances 0.000 claims description 5
- LEKJTGQWLAUGQA-UHFFFAOYSA-N acetyl iodide Chemical compound CC(I)=O LEKJTGQWLAUGQA-UHFFFAOYSA-N 0.000 claims description 5
- 238000006640 acetylation reaction Methods 0.000 claims description 5
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims description 5
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 5
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 5
- 229940011051 isopropyl acetate Drugs 0.000 claims description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 5
- 235000011009 potassium phosphates Nutrition 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- GHCMNGUSCXTDOE-DEOSSOPVSA-N [(2R)-1-(1,3-dioxoisoindol-2-yl)-3-(3-fluoro-4-morpholin-4-yl-N-phenylmethoxycarbonylanilino)propan-2-yl] acetate Chemical compound CC(=O)O[C@@H](CN(C(=O)OCc1ccccc1)c1ccc(N2CCOCC2)c(F)c1)CN1C(=O)c2ccccc2C1=O GHCMNGUSCXTDOE-DEOSSOPVSA-N 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 3
- ZZMOQXOGSNRJHT-QFIPXVFZSA-N benzyl N-[(2R)-3-(1,3-dioxoisoindol-2-yl)-2-hydroxypropyl]-N-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical group O[C@@H](CN(C(=O)OCc1ccccc1)c1ccc(N2CCOCC2)c(F)c1)CN1C(=O)c2ccccc2C1=O ZZMOQXOGSNRJHT-QFIPXVFZSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- NYQVCOGOJCKSJO-FQEVSTJZSA-N [(2R)-1-(1,3-dioxoisoindol-2-yl)-3-[3-fluoro-N-[(2-methylpropan-2-yl)oxycarbonyl]-4-morpholin-4-ylanilino]propan-2-yl] acetate Chemical compound CC(=O)O[C@@H](CN(C(=O)OC(C)(C)C)c1ccc(N2CCOCC2)c(F)c1)CN1C(=O)c2ccccc2C1=O NYQVCOGOJCKSJO-FQEVSTJZSA-N 0.000 claims description 2
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 claims 2
- QNECOMYSHCFCMH-SFHVURJKSA-N tert-butyl N-[(2R)-3-(1,3-dioxoisoindol-2-yl)-2-hydroxypropyl]-N-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical group CC(C)(C)OC(=O)N(C[C@H](O)CN1C(=O)c2ccccc2C1=O)c1ccc(N2CCOCC2)c(F)c1 QNECOMYSHCFCMH-SFHVURJKSA-N 0.000 claims 1
- 239000002585 base Substances 0.000 description 55
- 238000010992 reflux Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 28
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 19
- 238000002955 isolation Methods 0.000 description 19
- 239000007787 solid Substances 0.000 description 14
- 230000035484 reaction time Effects 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 238000010626 work up procedure Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 0 *C[C@](CNc(cc1F)ccc1N1CCOCC1)O Chemical compound *C[C@](CNc(cc1F)ccc1N1CCOCC1)O 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000011097 chromatography purification Methods 0.000 description 6
- 229940073584 methylene chloride Drugs 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 150000001342 alkaline earth metals Chemical class 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- NELIKABVJINPKX-ZDUSSCGKSA-N ethyl N-[(2R)-3-chloro-2-hydroxypropyl]-N-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical compound CCOC(=O)N(C[C@@H](O)CCl)c1ccc(N2CCOCC2)c(F)c1 NELIKABVJINPKX-ZDUSSCGKSA-N 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000004703 alkoxides Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- XKGUZGHMWUIYDR-UHFFFAOYSA-N benzyl n-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical compound C=1C=C(N2CCOCC2)C(F)=CC=1NC(=O)OCC1=CC=CC=C1 XKGUZGHMWUIYDR-UHFFFAOYSA-N 0.000 description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 4
- HLNQBKJNUTWWAM-CYBMUJFWSA-N ethyl N-(3-fluoro-4-morpholin-4-ylphenyl)-N-[[(2R)-oxiran-2-yl]methyl]carbamate Chemical compound CCOC(=O)N(C[C@@H]1CO1)c1ccc(N2CCOCC2)c(F)c1 HLNQBKJNUTWWAM-CYBMUJFWSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000004679 hydroxides Chemical class 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000010979 pH adjustment Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OLDRPBWULXUVTL-LLVKDONJSA-N (5r)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](CO)CN1C(C=C1F)=CC=C1N1CCOCC1 OLDRPBWULXUVTL-LLVKDONJSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- PBTHJVDBCFJQGG-UHFFFAOYSA-N methyl azide Chemical compound CN=[N+]=[N-] PBTHJVDBCFJQGG-UHFFFAOYSA-N 0.000 description 3
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- NQGHQKBSPVNNDS-NSHDSACASA-N (2r)-1-chloro-3-(3-fluoro-4-morpholin-4-ylanilino)propan-2-ol Chemical compound FC1=CC(NC[C@H](CCl)O)=CC=C1N1CCOCC1 NQGHQKBSPVNNDS-NSHDSACASA-N 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- FQGIBHQUVCGEAC-UHFFFAOYSA-N 3-Fluoro-4-morpholinoaniline Chemical compound FC1=CC(N)=CC=C1N1CCOCC1 FQGIBHQUVCGEAC-UHFFFAOYSA-N 0.000 description 2
- DTUQLFHOLZZAEY-UHFFFAOYSA-N 5-(oxan-2-yloxymethyl)-1,3-oxazolidin-2-one Chemical compound O1C(=O)NCC1COC1OCCCC1 DTUQLFHOLZZAEY-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000002894 chemical waste Substances 0.000 description 2
- 239000012069 chiral reagent Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- UDHMJZSYGFYAKR-UHFFFAOYSA-N CC(/[O]=C(/c1c2cccc1)\N(CCCN(C(O)=O)c(cc1F)ccc1N1CCOCC1)C2=O)=O Chemical compound CC(/[O]=C(/c1c2cccc1)\N(CCCN(C(O)=O)c(cc1F)ccc1N1CCOCC1)C2=O)=O UDHMJZSYGFYAKR-UHFFFAOYSA-N 0.000 description 1
- XCAYWHYOOWUNPL-UHFFFAOYSA-N CC(/[O]=C(/c1c2cccc1)\N(CCCN(C(OCc1ccccc1)=O)c(cc1F)ccc1N1CCOCC1)C2=O)=O Chemical compound CC(/[O]=C(/c1c2cccc1)\N(CCCN(C(OCc1ccccc1)=O)c(cc1F)ccc1N1CCOCC1)C2=O)=O XCAYWHYOOWUNPL-UHFFFAOYSA-N 0.000 description 1
- SFELMFCPXHSPQY-OAHLLOKOSA-N CC(NC[C@H](CN(C(O)=O)c(cc1F)ccc1N1CCOCC1)OC(C)=O)=O Chemical compound CC(NC[C@H](CN(C(O)=O)c(cc1F)ccc1N1CCOCC1)OC(C)=O)=O SFELMFCPXHSPQY-OAHLLOKOSA-N 0.000 description 1
- NODQFGKJUCINRR-UHFFFAOYSA-N CN.C1(C=2C(C(N1)=O)=CC=CC2)=O Chemical compound CN.C1(C=2C(C(N1)=O)=CC=CC2)=O NODQFGKJUCINRR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- FMYXNWGIQZTNHG-UHFFFAOYSA-N N-fluoro-4-morpholin-4-ylaniline Chemical compound FNC1=CC=C(C=C1)N1CCOCC1 FMYXNWGIQZTNHG-UHFFFAOYSA-N 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KCKQSNYMLDJWQG-UHFFFAOYSA-N O=C=Nc1ccc(CC2=CCCOCC2)c(F)c1 Chemical compound O=C=Nc1ccc(CC2=CCCOCC2)c(F)c1 KCKQSNYMLDJWQG-UHFFFAOYSA-N 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N O=Cc1ccccc1 Chemical compound O=Cc1ccccc1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- WVIGSMMIHUQDBA-UHFFFAOYSA-N OCCCN(C(O)=O)c(cc1F)ccc1N1CCOCC1 Chemical compound OCCCN(C(O)=O)c(cc1F)ccc1N1CCOCC1 WVIGSMMIHUQDBA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- BIWOYYCTPLLAHX-UHFFFAOYSA-N ethyl n-(3-fluoro-4-morpholin-4-ylphenyl)carbamate Chemical compound FC1=CC(NC(=O)OCC)=CC=C1N1CCOCC1 BIWOYYCTPLLAHX-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- BPELEZSCHIEMAE-UHFFFAOYSA-N salicylaldehyde imine Chemical compound OC1=CC=CC=C1C=N BPELEZSCHIEMAE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940061740 zyvox Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Definitions
- the present invention relates to improved, commercially viable and industrially advantageous processes for the preparation of Linezolid, in high yield and purity, using novel intermediates.
- U.S. Patent No. 5,688,792 (hereinafter referred to as the US'792 patent), assigned to Pharmacia & Upjohn Company, discloses a variety of oxazine and thiazine oxazolidinone derivatives and their stereochemically isomeric forms, processes for their preparation, pharmaceutical compositions comprising the derivatives, and method of use thereof.
- These compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, particularly gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms and acid-fast organisms.
- Linezolid a member of the oxazolidinone class of drugs and chemically named as N-[[(5S)-3-[3-fluoro-4-(4- mo ⁇ holinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA).
- Linezolid is represented by the following structural formula I:
- Linezolid infections of the skin and soft tissues and pneumonia (particularly hospital-acquired pneumonia).
- Linezolid is marketed by Pfizer under the trade names Zyvox (in the United States, United Kingdom, Australia, and several other countries), Zyvoxid (in Europe), and Zyvoxam (in Canada and Mexico).
- U.S. Patent No. 5,837,870 describes a process for the preparation of (5R)-5-(hydroxymethyl)-3- [3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone intermediate wherein, tetrahydrofuran is mixed with t-amyl alcohol, followed by the addition of butyl lithium in hexanes with agitation to produce a lithium t-amylate mixture, which is then added to solution of N- carbobenzyloxy-3-fluoro-4-morpholinyl aniline [obtained as per the process described in J.
- Tetrahydrofuran is mixed with S-(+)-3-chloro-l,2-propanediol, the resulting mixture is cooled to -16°C, followed by the addition of potassium t-butoxide in tetrahydrofuran while maintaining the temperature at less than -10°C. The resulting slurry is then stirred at - 14°C to 0°C for 1 hour and then added to the lithium anion mixture while maintaining both mixtures at 0°C, then rinsed in with tetrahydrofuran.
- the resulting slurry is stirred for 2 hours at 20-23 °C and then cooled to 6°C, followed by the addition of a mixture of citric acid monohydrate in water.
- the resultant liquid phases are separated and the lower aqueous phase is washed with ethyl acetate.
- the organic layers are combined and solvent is removed under reduced pressure.
- Heptane and water are added to the resulting mass and the solvent is removed by reduced pressure until a total volume of 5 ml remains.
- the precipitated product is collected by vacuum filtration and washed with water and then dried in a stream of nitrogen to produce (5 )-5-(hydroxymethyl)-3-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxazolidinone.
- the processes involve the use of expensive reagents including noble metal catalysts such as palladium on charcoal; and expensive chiral reagents such as ( ⁇ )-trans-l,2- diaminocyclohexane, in excess amounts, for preparing the starting material 5- (tetrahydro-pyran-2-yloxymethyl)-2-oxazolidinone which is difficult to synthesize; f) the processes involve the use of tedious and cumbersome procedures like prolonged reaction time periods, multiple process steps, column chromatographic purifications, multiple isolation /re-crystallizations - methods involving column chromatographic purifications are generally undesirable for large-scale operations, thereby making the process commercially unfeasible;
- the processes involve the use of multiple and excess amounts of hazardous solvents like n-hexane, heptanes, dioxane and tetrahydrofuran;
- the processes involve the use of highly toxic reagents like phosgene, triphosgene, pyridinium p-toluenesulfonate, pyridine and sodium azide;
- Desirable process properties include non-hazardous conditions, environmentally friendly and easy to handle reagents, reduced cost, greater simplicity, increased purity, and increased yield of the product, thereby enabling the production of Linezolid, in high purity and with high yield.
- Linezolid can be prepared in high purity and with high yield, by reacting N-[3-phthalimido-2-(R)- hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline with an alkyl or aryl chloroformate, or a dicarbonate reagent, in the presence of a base to produce an alkyl/aryl N-[3-phthalimido-2- (R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamate intermediate, which is then reacted with an acetylating agent to produce an alkyl/aryl N-[3-phthalimido-2-(R)- acetyloxypropyl]- -[3-fluoro-4-(4-mo holinyl) henyl]-ca ⁇ banlate, followed by deprotection with a suitable reagent in
- provided herein are efficient, industrially advantageous and environmentally friendly processes for the preparation of linezolid, in high yield and with high purity, using novel intermediates.
- the processes disclosed herein avoid the tedious and cumbersome procedures of the prior processes, thereby resolving the problems associated with the processes described in the prior art, which is more convenient to operate at lab scale and in commercial scale operations.
- Ri is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
- R ⁇ is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
- Rj is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
- Ri is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and Y is a leaving group such as a halogen or a sulfonyloxy group.
- Y is a leaving group such as a halogen or a sulfonyloxy group.
- Ri is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl
- Y is a leaving group such as a halogen or a sulfonyloxy group
- 'Ac' represents an acetyl group.
- Ri is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
- R ⁇ is CM 2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
- R ⁇ is C 1 -12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
- the present invention also encompasses the use of the novel compounds of formula III, IV, V, VI, VII, VIII, IX, X, XI and XII disclosed herein for preparing Linezolid.
- the overall process involves a reduced number of process steps, shorter reactions times and less expensive reagents thereby making the process cost effective; iii) the overall yield of the Linezolid product is increased and the purity of the product is increased without additional purifications such as multiple isolations and re- crystallizations or column chromatographic purifications;
- the processes avoid the use of expensive reagents including noble metal catalysts, e.g., palladium on charcoal, chiral reagents like ( ⁇ )-trans-l,2-diaminocyclohexane and 5- (tetrahydro-pyran-2-yloxymethyl)-2-oxazolidinone;
- noble metal catalysts e.g., palladium on charcoal
- chiral reagents like ( ⁇ )-trans-l,2-diaminocyclohexane and 5- (tetrahydro-pyran-2-yloxymethyl)-2-oxazolidinone
- the process avoids the use of tedious and cumbersome procedures like prolonged reaction time periods, extremely low temperatures (-78°C to -16°C), multiple process steps, column chromatographic purifications, multiple isolations, additional and excess amounts of solvents; and
- the radical R ⁇ in the compounds of formulae III, IV, V, VI, VII, VIII, IX, XI and XII is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
- the leaving group Y in the compound of formula VII & VIII is a halogen, or an alkyl or aryl sulfonyloxy group.
- the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
- the processes for the preparation of Linezolid using novel intermediates disclosed herein may be represented by a schematic diagram as depicted in scheme-9:
- Ri is CM 2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl;
- the radical Ri in the compounds of formulae III and IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
- alkyl denotes an aliphatic hydrocarbon group which may be straight or branched having 1 to 12 carbon atoms in the chain. Preferred alkyl groups have 1 to 6 carbon atoms in the chain.
- the alkyl may be substituted with one or more "cycloalkyl groups". Exemplary alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, t-butyl, and n-pentyl.
- cycloalkyl denotes a non-aromatic mono- or multicyclic ring system of 3 to 10 carbon atoms, preferably of about 5 to about 10 carbon atoms.
- exemplary monocyclic cycloalkyl groups include cyclopentyl, cyclohexyl, cycloheptyl and the like.
- aralkyl denotes an aryl-alkyl group wherein the aryl and alkyl are as herein described. Preferred aralkyls contain a lower alkyl moiety. Exemplary aralkyl groups include benzyl, 2-phenethyl and naphthalenemethyl.
- aryl denotes an aromatic monocyclic or multicyclic ring system of 6 to 10 carbon atoms.
- the aryl is optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
- exemplary aryl groups include phenyl, tolyl or naphthyl.
- the novel intermediate compounds of Linezolid disclosed herein are obtained as solid state forms in substantially pure form.
- substantially pure refers to the solid state form of linezolid intermediates, disclosed herein, having a purity of greater than about 90 wt%, specifically greater than about 95 wt%, more specifically greater than about 98 wt%, and still more specifically greater than about 99 wt%.
- the purity is preferably measured by High Performance Liquid Chromatography (HPLC).
- HPLC High Performance Liquid Chromatography
- the purity of solid state form of linezolid intermediates obtained by the processes disclosed herein can be about 95% to about 99%, or about 98% to about 99.9%, as measured by HPLC.
- salts may include acid addition salts and base addition salts.
- Acid addition salts include the salts that are derived from organic and inorganic acids.
- the acid addition salts are derived from a therapeutically acceptable acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, oxalic acid, acetic acid, propionic acid, phosphoric acid, succinic acid, maleic acid, fumaric acid, citric acid, glutaric acid, tartaric acid, benzenesulfonic acid, toluenesulfonic acid, di- p-toluoyl-L-(+)-tartaric acid, malic acid, ascorbic acid, and the like.
- a therapeutically acceptable acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, oxalic acid, acetic acid, propionic acid, phosphoric acid, succinic acid, maleic acid, fumaric acid, citric acid, glutaric acid, tartaric acid, benzenesul
- Base addition salts may be derived from an organic or an inorganic base.
- the base addition salts are derived from alkali or alkaline earth metals such as sodium, calcium, potassium and magnesium; ammonium salt, organic amines such as ethylamine, tert-butylamine, diethylamine, diisopropylamine, and the like.
- Exemplary acetylating agents used in step-(a) include, but are not limited to, acetyl halide such as acetyl chloride, acetyl bromide, acetyl iodide; acetic anhydride, sodium acetate, and the like, or a combination thereof.
- acetyl halide such as acetyl chloride, acetyl bromide, acetyl iodide
- acetic anhydride sodium acetate, and the like, or a combination thereof.
- a most specific acetylating agent is acetic anhydride.
- the reaction in step-(a) can be carried out in the presence or absence of a reaction inert solvent. In one embodiment, the reaction in step-(a) is carried out in the absence of a solvent. In another embodiment, the reaction in step-(a) is optionally carried out in the presence of a first solvent.
- solvent also includes mixture of solvents.
- Exemplary first solvents used in step-(a) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- the first solvent used in step-(a) is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n-hexane, n- heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl-tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and
- the acetylating agent in step-(a) is used in a ratio of about 1 to 6 equivalents, specifically about 3 to 5 equivalents, with respect to (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV in order to ensure a proper course of the reaction.
- the acetylation in step-(a) is optionally carried out in the presence of a base.
- the base is an organic base or inorganic base, and most specifically an inorganic base.
- Exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates, phosphates and carbonates of alkali or alkaline earth metals; ammonia, collidine, trimethylamine, triethylamine, tributylamine, diisopropylethylamine, N- methylmorpholine, 1-alkylimidazole and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
- DBU diazabicyclo[5.4.0]undec-7-ene
- Specific bases are aqueous ammonia, potassium phosphate, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide, potassium tert-butoxide, or a combination thereof; and most specifically potassium carbonate, sodium hydroxide and potassium hydroxide.
- reaction temperature and time period will ordinarily depend on the starting compounds and the solvent/reagent employed in the reaction.
- the acetylation reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 25°C to the reflux temperature of the solvent used, and more specifically at about 30°C to about 60°C.
- the reaction time may vary between about 1 hour to about 10 hours, specifically about 2 hours to about 7 hours, and more specifically about 4 hours to about 6 hours.
- the reaction mass containing the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III obtained in step-(a) may be subjected to usual work up such as a washing, an extraction, a pH adjustment, an evaporation, a layer separation, a decolonization, or a combination thereof.
- the reaction mass may be used directly in the next step to produce the Linezolid of formula I, or the compound of formula III may be isolated and/or recrystallized and then used in the next step.
- the excess acetic anhydride may be removed by distillation.
- the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III is isolated and/or re-crystallized from a suitable solvent by conventional methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, evaporation, vacuum distillation, or a combination thereof.
- the solvent used for isolating and/or recrystallizing the (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III is selected from the group consisting of water, an alcohol, a ketone, an ether, an ester, a hydrocarbon solvent, a halogenated hydrocarbon, and mixtures thereof.
- the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, tetrahydrofuran, 2-methyl-tetrahydrofuran, diisopropyl ether, methyl tert-butyl ether, ethyl acetate, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, dichloromethane, dichloroethane, chloroform, and mixtures thereof.
- a most specific (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III prepared by the process described herein is N-[3-phthalimido-2- (R)-acetyloxypropyl]-N-[3-fluoro-4-(4-mo ⁇ holinyl) phenyl] -carbamic acid ethyl ester of formula Ilia (formula III, wherein Ri is ethyl):
- a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III prepared by the process described herein is N-[3- phthalimido-2-(R)-acetyloxy ⁇ ropyl]-N-[3-fluoro-4-(4-mo holinyl) phenyl] -carbamic acid tert-butyl ester of formula Illb (formula III, wherein Ri is tert-butyl):
- a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III prepared by the process described herein is N-[3- phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl]-carbamic acid benzyl ester of formula IIIc (formula III, wherein Ri is benzyl):
- the reagent used in step-(b) is a primary amine formation agent.
- Exemplary primary amine formation agents used in step-(b) include, but are not limited to, hydrazine hydrate, methyl amine, and the like.
- a most specific reagent is hydrazine hydrate or aqueous methyl amine.
- the reaction in step-(b) is optionally carried out in the presence of a base.
- the base is an organic or inorganic base, and most specifically an inorganic base, selected from the group as described hereinabove.
- Specific bases are aqueous ammonia, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide and potassium tert-butoxide; and most specifically potassium carbonate.
- reaction in step-(b) is carried out in the presence of a second solvent.
- Exemplary second solvents used in step-(b) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- the second solvent used in step-(b) is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n- hexane, n-heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl- tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, ⁇ , ⁇ -dimethylformamide, N,N- dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane,
- the reagent in step-(b) is used in a ratio of about 1 to 5 equivalents, specifically about 3 to 5 equivalents, with respect to the (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III in order to ensure a proper course of the reaction.
- the reaction in step-(b) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used.
- the reaction time may vary between about 3 hours to about 10 hours, and specifically about 4 hours to about 6 hours.
- the reaction mass containing the Linezolid of formula I obtained may be subjected to usual work up such as a washing, an extraction, an evaporation, a pH adjustment etc., followed by isolation and/or recrystallization from a suitable solvent by conventional methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, evaporation, vacuum distillation, or a combination thereof.
- novel intermediate compounds namely (R)-amino-2- acetyloxypropyl-carbamate compound of formula V and (R)-acetamido-2-hydroxypropyl- carbamate compound of formula XI, are formed when reacting the (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III with the primary amine formation agent and these novel compounds may be isolated using the methods described herein.
- the novel compounds of formula V and formula XI are characterized by having the following structural formulae:
- reaction conditions and parameters may permit the isolation of the compounds of formulae V and XI.
- reaction conditions and parameters e.g., temperature, time, reagent, base, solvent, etc.
- use of mild reaction conditions e.g. low temperatures and mild base
- application of heat to the compound of formula V optionally in the presence of a base may permit the isolation of the compound of formula XL
- the reaction time may vary between about 30 minutes to about 10 hours and specifically about 1 hour to about 3 hours.
- the isolated novel intermediate compounds of formulae V and XI may be further converted into linezolid of formula I using the methods described herein.
- the solvent used for washing, extracting, isolating and/or recrystallizing the pure Linezolid of formula I is selected from the group as described herein above.
- the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, tetrahydrofuran, 2-memyl-tetrahydrofuran, diisopropyl ether, methyl tert-butyl ether, ethyl acetate, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, dichloromethane, dichloroethane, chloroform, and mixtures thereof.
- the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, ethyl acetate, dichloromethane, and
- the isolation is carried out by cooling the reaction mass at a temperature of below about 35°C, followed by the addition of water at a temperature of about 10°C to about 35°C, and more specifically at a temperature of about 20°C to about 30°C.
- the resulting mass is optionally stirred at a temperature of about 10°C to about 35°C for at least 10 minutes, and most specifically at a temperature of about 20°C to about 30°C for about 15 minutes to about 2 hours.
- the isolation is carried out by cooling the reaction mass while stirring at a temperature below about 30°C and more specifically at about 20°C to about 30°C.
- the solid obtained is collected by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
- novel (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV employed as intermediate in the process for manufacture of Linezolid disclosed herein allows the product to be easily isolated and purified, thereby producing a product with 70- 80% overall yield.
- Ri is Ci -12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group;
- the radical Ri in the compounds of formula III is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
- Ri is C ⁇ .n straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group;
- the radical Ri in the compounds of formulae III & IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R] is methyl, ethyl, benzyl or tert-butyl.
- an improved and cost effective process for the preparation of Linezolid of formula I, or an enantiomeric form or a mixture of enantiomeric forms thereof which comprises:
- the radical R t in the compounds of formula IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
- the reagent used in step-(a) is a primary amine formation agent.
- Exemplary primary amine formation agents used in step-(a) include, but are not limited to, hydrazine hydrate, methyl amine, and the like.
- a most specific reagent is hydrazine hydrate or aqueous methyl amine.
- the reaction in step-(a) is carried out in the presence of a base.
- the base is an organic or inorganic base, and most specifically an inorganic base, selected from the group as described hereinabove.
- Specific bases are aqueous ammonia, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide and potassium tert-butoxide; and most specifically potassium carbonate.
- the reaction in step-(a) is carried out in the presence of a solvent.
- a solvent used in step-(a) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- the solvent used in step-(a) is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl-tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures
- the solvent is selected from the group consisting of methanol, ethanol, isopropanol, acetone, and mixtures thereof.
- the reagent in step-(a) is used in a ratio of about 1 to 5 equivalents, specifically about 3 to 5 equivalents, with respect to the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV in order to ensure a proper course of the reaction.
- the reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used.
- the reaction time may vary between about 2 hours to about 8 hours, and specifically about 3 hours to about 4 hours.
- reaction mass containing the (S)-N-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo- 5-oxazolidinyl-methyl amine of formula II obtained in step-(a) may be subjected to usual work up methods as described hereinabove.
- the reaction mass may be used directly in the next step to produce the Linezolid of formula I, or the compound of formula II may be isolated and/or recrystallized and then used in the next step.
- the (S)-N-[3-fiuoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl-methyl amine of formula II is isolated and/or re-crystallized from a suitable solvent by the methods as described hereinabove.
- reaction conditions and parameters may permit the isolation of the compound of formula VI.
- reaction conditions and parameters e.g., temperature, time, reagent, base, solvent, etc.
- mild reaction conditions e.g. low temperatures and mild base
- the isolated novel intermediate compound of formulae VI may be further converted into linezolid of formula I using the methods described herein.
- the solvent used for isolating and/or recrystallizing the (S)-N-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxo-5-oxazolidinyl-methyl amine of formula II is selected from the group as described above for such purpose.
- the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, tetrahydrofuran, 2-methyl-tetrahydrofuran, diisopropyl ether, methyl tert-butyl ether, ethyl acetate, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, dichloromethane, dichloroethane, chloroform, and mixtures thereof.
- step-(b) The acetylation reaction in step-(b) is carried out by the methods known in the art.
- Exemplary acetylating agents used in step-(b) include, but are not limited to, acetyl halide such as acetyl chloride, acetyl bromide, acetyl iodide; acetic anhydride, sodium acetate, and the like, or a combination thereof.
- acetyl halide such as acetyl chloride, acetyl bromide, acetyl iodide
- acetic anhydride sodium acetate, and the like, or a combination thereof.
- a most specific acetylating agent is acetic anhydride.
- reaction mass containing the linezolid of formula I obtained in step-(b) may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent using the methods as described herein above.
- R ⁇ is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; with a suitable reagent, optionally in the presence of a base, to produce the aminomethyl compound of formula II, or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
- the radical Rj in the compounds of formulae IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R ⁇ is methyl, ethyl, benzyl or tert-butyl.
- R ⁇ is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; comprising reacting N-[3-phthalimido-2-(R)- hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII:
- a suitable activating agent optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XlVb:
- radical Ri is as defined in Formula IV; to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
- XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
- 4-(4-morpholinyl)aniline of formula XIII as used herein as starting material is a known compound and can be obtained by the processes described in the prior art, for example, the processes described in the U.S. Patent No. 7,429,661 B2 assigned to Symed Labs Limited
- the reaction between the compounds of formula XIII and XlVa or XlVb is carried out in the presence of a base.
- the base is an organic or inorganic base, and most specifically an organic base.
- Exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates and carbonates of alkali or alkaline earth metals; ammonia, collidine, trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, and 1-alkylimidazole.
- Specific bases are trimethylamine, tributylamine, triethylamine, diisopropylethylamine and N-methylmorpholine; and most specifically diisopropylethylamine.
- the reaction between the compounds of formula XIII and XlVa or XlVb is carried out in the presence of a solvent.
- a solvent include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- a most specific solvent is dichloromethane.
- the activating agent of formula XlVa or XlVb is used in a ratio of about 1 to 3 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the N- [3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-mo ⁇ holinyl)aniline of formula XIII in order to ensure a proper course of the reaction.
- the reaction between the compounds of formula XIII and the activating agent is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 10°C to the reflux temperature of the solvent used, and most specifically at a temperature of about 20°C to about 40°C.
- the reaction time may vary between about 30 minutes to about 8 hours, specifically about 1 hour to about 5 hours, and more specifically about 1 hour to about 2 hours.
- reaction mass containing the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV obtained may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent using the methods as described herein above.
- the solvent used for isolating and/or recrystallizing the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV is selected from the group as described herein above.
- a most specific (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV prepared by the process described herein is N-[3-phthalimido-2- (R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester of formula IVa (formula IV, wherein R ⁇ is ethyl):
- a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV prepared by the process described herein is N-[3- phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-mo holinyl)phenyl]-carbamic acid tert-butyl ester of formula IVb (formula IV, wherein Ri is tert-butyl):
- a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV prepared by the process described herein is N-[3- phthalimido-2-(R)-hydroxypropyl] -N- [3 -fluoro-4-(4-morpholinyl)phenyl] -carbamic acid benzyl ester of formula IVc formula IV, wherein Rj is benzyl):
- Ri is straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl; which comprises: reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3- epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
- Y is a leaving group such as a halogen or a sulfonyloxy group
- activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XI Vb:
- radical Ri is as defined in Formula IV; to produce an (R)-2- hydroxypropyl-carbamate compound of formula VII or an (R)-2,3-epoxypropyl- carbamate compound of formula IX:
- step-(a) reacting the (R)-2-hydroxypropyl-carbamate compound of formula VII or the (R)-2,3- epoxypropyl-carbamate compound of formula IX obtained in step-(a) with potassium phthalimide, optionally in the presence of a base, to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
- the radical Ri in the compounds of formulae IV, VII, IX, XlVa & XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R ⁇ is methyl, ethyl, benzyl or tert-butyl.
- the leaving group Y in the compounds of formulae VII and XV is a halogen, or an alkyl or aryl sulfonyloxy group.
- the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
- the (R)-2-hydroxypropyl-aniline compound of formula XV as used herein as starting material is a known compound and can be obtained by the processes described in the prior art, for example, the processes described in the U.S. Patent No. 7,307,163 B2 assigned to Symed Labs Limited (the present applicant).
- the reaction in step-(a) is carried out in the presence of a base.
- the base is an organic or inorganic base, and most specifically an organic base, selected from the group as described herein above.
- Exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates and carbonates of alkali or alkaline earth metals; ammonia, collidine, trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, and 1-alkylimidazole.
- Specific bases are trimethylamine, tributylamine, triethylamine, diisopropylethylamine and N-methylmorpholine; and most specifically diisopropylethylamine.
- the reaction in step-(a) is carried out in the presence of a solvent.
- a solvent used herein include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- a most specific solvent is dichloromethane.
- the activating agent of formula XlVa or XlVb is used in a ratio of about 1 to 3 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the (R)-2-hydroxypropyl-aniline compound of formula XV, or N-[2(R)-2,3-epoxypropyl]-3- fluoro-4-(4-morpholinyl)aniline of formula X, in order to ensure a proper course of the reaction.
- the reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 10°C to the reflux temperature of the solvent used, and most specifically at a temperature of about 20°C to about 40°C.
- the reaction time may vary between about 30 minutes to about 8 hours, specifically about 1 hour to about 5 hours, and more specifically about 1 hour to about 2 hours.
- reaction mass containing the (R)-2-hydroxypropyl-carbamate compound of formula VII or an (R)-2,3-epoxypropyl-carbamate compound of formula IX obtained in step-(a) may be subjected to usual work up such as a washing, an extraction, a pH adjustment, an evaporation, a layer separation, a decolorization, or a combination thereof.
- the reaction mass may be used directly in the next step to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV, or the compound of formula VII or IX may be isolated and/or recrystallized and then used in the next step.
- the (R)-2-hydroxypropyl-carbamate compound of formula VII or an (R)-2,3-epoxypropyl-carbamate compound of formula IX is isolated and/or re- crystallized from a suitable solvent by conventional methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, evaporation, vacuum distillation, or a combination thereof.
- the solvent used for isolating and/or recrystallizing the (R)-2-hydroxypropyl- carbamate compound of formula VII or an (R)-2,3-epoxypropyl-carbamate compound of formula IX is selected from the group as described herein above.
- the reaction in step-(b) is optionally carried out in the presence of a base.
- the base is an organic or inorganic base selected from the group as described hereinabove.
- the reaction in step-(b) is carried out in the presence of a solvent.
- a solvent used in step-(b) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- the solvent used in step-(b) is selected from the group acetonitrile, propionitrile, ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ -dimethylacetarnide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specific solvents are acetonitrile, N,N-dimethylformamide, and mixtures thereof.
- the potassium phthalimide in step-(b) is used in a ratio of about 1 to 2 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the (R)-2- hydroxypropyl-carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate Compound of formula IX in order to ensure a proper course of the reaction.
- the reaction in step-(b) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used.
- the reaction time may vary between about 1 hour to about 10 hours, and specifically about 4 hours to about 6 hours.
- reaction mass containing the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV obtained may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent by the methods as described herein above.
- the solvent used for washing, extracting, isolating and/or recrystallizing the (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV is selected from the group as described herein above.
- step-(b) The solid obtained in step-(b) is collected by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
- a most specific (R)-2-hydroxypropyl-carbamate compound of formula VII prepared by the process described herein is N-[3-Chloro-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester of formula Vila (formula VII, wherein R ⁇ is ethyl and Y is CI):
- a most specific (R)-2,3-epoxypropyl-carbamate compound of formula IX prepared by the process described herein is N-[2(R)-2,3-epoxypropyl]-N-[3- fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester of formula IXa (formula IX, wherein Ri is ethyl):
- Rj is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; comprising reacting the (R)-2-hydroxypropyl- carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate compound of formula IX:
- Rj is as defined in Formula IV
- Y is a leaving group such as a halogen or a sulfonyloxy group
- potassium phthalimide optionally in the presence of a base, to produce the (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
- the radical Ri in the compounds of formulae IV, VII & IX is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
- the leaving group Y in the compound of formula VII is a halogen, or an alkyl or aryl sulfonyloxy group.
- the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
- Rj is CM 2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl
- Y is a leaving group such as a halogen or a sulfonyloxy group; comprising reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
- Y is a leaving group such as a halogen or a sulfonyloxy group
- activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula
- XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Rj is methyl, ethyl, benzyl or tert-butyl.
- the leaving group Y in the compound of formula VII & XV is a halogen, or an alkyl or aryl sulfonyloxy group.
- the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and tnfluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
- R ⁇ is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; which comprises:
- Y is a leaving group such as a halogen or a sulfonyloxy group
- XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R ⁇ is methyl, ethyl, benzyl or tert-butyl.
- the leaving group Y in the compound of formula XV is a halogen, or an alkyl or aryl sulfonyloxy group.
- the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; ⁇ more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
- the reaction in step-(a) is optionally carried out presence of a base.
- the base is an organic or inorganic base selected from the group as described hereinabove.
- the reaction in step-(a) is carried out in the presence of a solvent.
- a solvent used in step-(a) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- the solvent used in step-(a) is selected from the group acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specific solvents are acetonitrile, ⁇ , ⁇ -dimethylformamide, and mixtures thereof.
- the potassium phthalimide in step-(a) is used in a ratio of about
- the reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used.
- the reaction time may vary between about 1 hour to about 10 hours, and specifically about 3 hours to about 6 hours.
- reaction mass containing the N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro- 4-(4-morpholinyl)aniline of formula XIII obtained in step-(a) may be subjected to usual work up such as a washing, an extraction, a pH adjustment, an evaporation, a layer separation, a decolorization, or a combination thereof.
- the reaction mass may be used directly in the next step to produce the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV, or the compound of formula XIII may be isolated and/or recrystallized and then used in the next step.
- the N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4- morpholinyl)aniline of formula XIII is isolated and/or re-crystallized from a suitable solvent by the methods described herein above.
- the solvent used for isolating and/or recrystallizing the N-[3-phthalimido-2-(R)- hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII is selected from the group as described herein above.
- the reaction in step-(b) is carried out in the presence of a base.
- the base is an organic or inorganic base, and most specifically an organic base, selected from the group as described herein above.
- Specific bases are trimethylamine, tributylamine, triethylamine, diisopropylethylamine and N-methylmorpholine; and most specifically diisopropy lethylamine .
- the reaction in step-(b) is carried out in the presence of a solvent.
- a solvent used herein include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- a most specific solvent is dichloromethane.
- the activating agent of formula XlVa or XlVb is used in a ratio of about 1 to 3 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the N- [3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-mo holinyl)aniline of formula XIII in order to ensure a proper course of the reaction.
- reaction in step-(b) is carried out at a temperature of about
- reaction time may vary between about 30 minutes to about 8 hours, specifically about 1 hour to about 5 hours, and more specifically about 1 hour to about 2 hours.
- reaction mass containing the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV obtained may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent by the methods as described herein above.
- Y is a leaving group such as a halogen or a sulfonyloxy group; with a base to produce the N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-mo holinyl)aniline of formula X or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
- the leaving group Y in the compound of formula XV is a halogen, or an alkyl or aryl sulfonyloxy group.
- the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
- the base is an organic or inorganic base, and most specifically an inorganic base.
- exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates and carbonates of alkali or alkaline earth metals; ammonia, collidine, trimethylamine, tnbutylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, and 1-alkylimidazole.
- Specific bases are aqueous ammonia, potassium phosphate, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide, potassium tert-butoxide, or a combination thereof; and most specifically potassium carbonate, sodium hydroxide and potassium hydroxide.
- reaction between the (R)-2-hydroxypropyl-aniline compound of formula XV and the base is carried out in the presence of a solvent.
- Exemplary solvents used herein include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
- the solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl-tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof.
- Most specific solvents are
- the reaction between the (R)-2-hydroxypropyl-aniline compound of formula XV and the base is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 10°C to the reflux temperature of the solvent used, and most specifically at a temperature of about 20°C to about 40°C.
- the reaction time may vary between about 1 to about 16 hours, specifically about 6 hour to about 15 hours, and more specifically about 12 hours to about 14 hours.
- reaction mass containing the of N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4- morpholinyl)aniline of formula X obtained may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent using the methods as described herein above.
- the solids obtained in any of the above process steps described hereinabove may be collected by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
- the processes of the invention are adapted to the preparation of oxazolidinone derivatives, preferably Linezolid, in high enantiomeric and chemical purity.
- novel intermediate compounds of formulae III, IV, V, VI, VII, VIII, IX, X, XI and XII employed for the preparation of linezolid disclosed herein allows the product to be easily isolated and purified, thereby producing a product with 60-80% overall yield.
- the highly pure linezolid obtained by the above processes may be further dried in, for example, a Vacuum Tray Dryer, a Rotocon Vacuum Dryer, a Vacuum Paddle Dryer or a pilot plant Rota vapor, to further lower residual solvents. Drying can be carried out under reduced pressure until the residual solvent content reduces to the desired amount such as an amount that is within the limits given by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (“ICH”) guidelines.
- ICH International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
- the drying is carried out at atmospheric pressure or reduced pressures, such as below about 200 mm Hg, or below about 50 mm Hg, at temperatures such as about 35°C to about 90°C, and specifically at about 75°C to about 85°C.
- the drying can be carried out for any desired time period that achieves the desired result, such as times about 1 to 20 hours. Drying may also be carried out for shorter or longer periods of time depending on the product specifications. Temperatures and pressures will be chosen based on the volatility of the solvent being used and the foregoing should be considered as only a general guidance. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer, and the like.
- the highly pure linezolid obtained by the processes disclosed herein has a total purity, includes both chemical and enantiomeric purity, of greater than about 99%, specifically greater than about 99.5%, more specifically greater than about 99.9%, and most specifically greater than about 99.95% as measured by HPLC.
- Ri is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
- a most specific (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III disclosed herein is N-[3-phthalimido-2-(R)-acetyloxypropyl]-N- [3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid ethyl ester of formula Ilia (formula III, wherein R ⁇ is ethyl):
- a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III disclosed herein is N-[3-phthalimido-2-(R)- acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid tert-butyl ester of formula Illb (formula III, wherein Ri is tert-butyl):
- a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III disclosed herein is N-[3-phthalimido-2-(R)- acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid benzyl ester of formula IIIc (formula III, wherein R ⁇ is benzyl):
- R ⁇ is CM 2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
- a most specific (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV disclosed herein is N-[3-phthalimido-2-(R)-hydroxypropyl]-N-
- a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV disclosed herein is N-[3-phthalimido-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-mo holinyl)phenyl]-carbamic acid tert-butyl ester of formula IVb (formula IV, wherein R ⁇ is tert-butyl):
- a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV disclosed herein is N-[3-phthalimido-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid benzyl ester of formula IVc (formula IV, wherein Rj is benzyl):
- R ⁇ is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
- Ri is C .n straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and Y is a leaving group such as a halogen or a sulfonyloxy group.
- Ri is C ⁇ straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl
- Y is a leaving group such as a halogen or a sulfonyloxy group
- 'Ac' represents an acetyl group
- R ⁇ is C1.12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
- R ⁇ is C 1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
- the radical in the compounds of formulae III, IV, V, VI, VII, VIII, IX, XI and XII is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, olyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R is methyl, ethyl, benzyl or tert-butyl.
- the leaving group Y in the compound of formulae VII & VIII is a halogen, or an alkyl or aryl sulfonyloxy group.
- the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
- the present invention also encompasses the use of the novel compounds of formulae III, IV, V, VI, VII, VIII, IX, X, XI and XII disclosed herein for preparing Linezolid.
- Step-1 N-[3-Phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid ethyl ester
- Acetic anhydride (51 g, 0.5 moles) was added to N-[3-phthalimido-2-(R)-hydroxypropyl]- N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester and the contents were heated to 50-55°C, followed by maintaining the reaction mixture at the same temperature for 4 to 6 hours.
- Step-1 N-[3-Phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)
- N-Ethyldiisopropyl amine (16 g, 0.124 mol) was added to a suspension of N-[3- phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline (39.9 g, 0.1 mol) in methylene chloride (360 ml) at 25-30°C.
- Ethyl chloroformate (12 g, 0.11 mol) was slowly added to the resulting solution at 25-30°C during the time period of about 30 minutes, followed by stirring the mass at the same temperature for 1 to 2 hours.
- reaction mass was washed subsequently with 4N hydrochloric acid solution (100 ml), water (100 ml) and saturated brine solution (100 ml) and then concentrated the resulting mass to produce 45 g of N- [3 -phthalimido-2-(R)-hydroxypropyl] -N- [3 -fluoro-4-(4-morpholinyl)phenyl] - carbamic acid ethyl ester as a residue (Yield: 95.5%; Purity by HPLC: 98.5%).
- Step-1 N-[3-Chloro-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]- carbamic acid ethyl ester
- N-Ethyldiisopropyl amine (16.1 g, 0.125 mol) was added to a solution of N-[3-chloro-2- (R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline (28.85 g, 0.1 mol) in methylene chloride (285 ml) at 25-30°C.
- Ethyl chloroformate 11 g, 0.1 mol was added to the resulting solution at 25-30°C, followed by stirring the solution at the same temperature for 4 hours.
- reaction mass was washed subsequently with 10% hydrochloric acid solution (100 ml), water (100 ml) and saturated brine solution (100 ml) and then concentrated the resulting mass under reduced pressure to produce 35 g of N-[3-chloro-2-(R)- hydroxypropyl]-N- [3 -fluoro-4-(4-morpholinyl)phenyl] -carbamic acid ethyl ester as an oily residue (Yield: 97.2%).
- Step-2 N-[3-Phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)
- Potassium phthalimide (21.5 g, 0.116 mol) was added to a solution of N-[3-chloro-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester (35 g, 0.097 mol) in dimethylformamide (87.5 ml) and the resulting suspension was heated to 100-110°C and then maintained for 3 hours at the same temperature. The reaction mass was cooled to room temperature (25-30°C), followed by the addition of water (400 ml) and then stirring the mass for 1 hour.
- Step-1 N-[2(R)-2 -epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline
- Step-2 N-[2(R)-2,3-epoxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester
- N-Ethyldiisopropyl amine (15.6 g, 0.12 mol) was added to a solution of N-[2(R)-2,3- epoxypropyl]-3-fluoro-4-(4-mo holinyl)aniline (24.6 g, 0.097 mol) in methylene chloride (250 ml) at 25-30°C.
- Ethyl chloroformate 11 g, 0.1 mol was added to the resulting solution at 25-30°C, followed by stirring the solution at the same temperature for 2 hours.
- Potassium phthalimide (18.5 g, 0.1 mol) was added to a solution of N-[2(R)-2,3- epoxypropyl]-N- [3 -fluoro-4-(4-morpholinyl)phenyl] -carbamic acid ethyl ester (27.9 g, 0.086 mol) in dimethylformamide (80 ml) and the resulting suspension was heated to 90- 95°C, followed by maintaining the resulting mass for 3 hours at the same temperature. The reaction mass was cooled to room temperature (25-30°C), followed by the addition of water (400 ml) and then stirring the mass for 1 hour.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Provided herein are improved, commercially viable and industrially advantageous processes for the preparation of Linezolid, in high yield and purity, using novel intermediates. In one aspect, provided herein are efficient, industrially advantageous and environmentally friendly processes for the preparation of linezolid, in high yield and with high purity, using novel intermediates. The processes disclosed herein avoid the tedious and cumbersome procedures of the prior processes, thereby resolving the problems associated with the processes described in the prior art, which is more convenient to operate at lab scale and in commercial scale operations.
Description
IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING
NOVEL INTERMEDIATES
FIELD OF THE INVENTION
The present invention relates to improved, commercially viable and industrially advantageous processes for the preparation of Linezolid, in high yield and purity, using novel intermediates.
BACKGROUND OF THE INVENTION
U.S. Patent No. 5,688,792 (hereinafter referred to as the US'792 patent), assigned to Pharmacia & Upjohn Company, discloses a variety of oxazine and thiazine oxazolidinone derivatives and their stereochemically isomeric forms, processes for their preparation, pharmaceutical compositions comprising the derivatives, and method of use thereof. These compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, particularly gram-positive aerobic bacteria such as multiply-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms and acid-fast organisms. Among them, Linezolid, a member of the oxazolidinone class of drugs and chemically named as N-[[(5S)-3-[3-fluoro-4-(4- moφholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). Linezolid is represented by the following structural formula I:
The main indications of linezolid are infections of the skin and soft tissues and pneumonia (particularly hospital-acquired pneumonia). Linezolid is marketed by Pfizer
under the trade names Zyvox (in the United States, United Kingdom, Australia, and several other countries), Zyvoxid (in Europe), and Zyvoxam (in Canada and Mexico).
The synthesis of Linezolid was first described in the US' 792 patent. According to the US'792 patent, the Linezolid is prepared by a process as depicted in scheme 1:
Scheme-1:
(S)-N-[[3-[3-Fluoro-4-morpholinyl]
10%Pd/C,H2 phenyl]-2-oxo-5-oxazolidinyl]methyl]- phthalimide
Acetic anhydride
Ethanol aq.CHjNH2
(S)-N-[[3-[3-Fluoro-4-morpholinyl]phenyl]- 2-oxo-5-oxazolidinyl]methyl]acetamide (S)-N-[[3-[3-fluoro-4-morpholinyl]
phenyl]-2-oxo-5-oxazolidinyl]methyl]-
(Linezolid) amine
The synthesis of Linezolid as described in the US'792 patent involves the following main reaction steps: a) 3-Fluoro-4-morpholinyl aniline is reacted with benzyl chloroformate in the presence of sodium bicarbonate to produce N-carbobenzyloxy-3- fluoro-4-morpholinyl aniline; b) the N-carbobenzyloxy-3-fluoro-4-morpholinyl aniline is reacted with a solution of ( )-glycidyl butyrate in tetrahydrofuran in the presence of n- butyl lithium/hexane at a temperature of -78°C under nitrogen atmosphere, followed by
tedious work-up and isolation methods to produce the (5R)-5-(hydroxymethyl)-3-[3- fluoro-4-(4-mo holinyl)phenyl]-2-oxazolidinone; c) the (5R)-5-(Hydroxymethyl)-3-[3- fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone is reacted with methanesulfonyl chloride in the presence of triethylamine in methylene chloride solvent under nitrogen atmosphere to produce (5R)-[[3-[3-fluoro-4-(4-mo holinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl methane sulfonate; d) (i) the (5R)-[[3-[3-fluoro-4-(4-moφholinyl)]phenyl]-2-oxo-5- oxazolidinyl]methyl methane sulfonate is reacted with sodium azide to produce (5R)-[[3- [3-fluoro-4-(4-morpholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl azide, or alternatively (ii) the (5R)-[[3 - [3 -fluoro-4-(4-nK^holinyl)]phenyl] -2-oxo-5-oxazolidinyl]methyl methane sulfonate intermediate is reacted with potassium phthalimide to produce (S)-N- [[3-[3-Fluoro-4-[4-moφholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] phthalimide; e) (i) the (5R)-[[3-[3-fluoro-4-(4-moφholinyl)]phenyl]-2-oxo-5-oxazolidinyl]methyl azide intermediate is hydrogenated in the presence of 10% palladium/carbon to produce (S)-N- [[3-[3-Fluoro-4-[4-moφholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] amine, or (ii) the (S)-N-[[3-[3-Fluoro-4-[4-moφholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide intermediate is then reacted with aqueous methyl amine to produce (S)-N-[3-fiuoro-4-(4- moφholinyl)phenyl]-2-oxo-5-oxazolidinyl-methyl amine; and f) the (S)-N-[3-fluoro-4-(4- moφholinyl)phenyl]-2-όxo-5-oxazolidinyl-methyl amine intermediate is then subjected to acetylation with acetic anhydride to produce Linezolid.
The processes for the preparation of Linezolid as described in the aforementioned prior art suffer from several disadvantages and limitations. The main disadvantage of the prior art processes is that the reaction between N-carbobenzyloxy-3-fluoro-4-irK^holinyl aniline and (R)-glycidyl butyrate in tetrahydrofuran in the presence of n-butyl lithium/hexane should be performed at extremely low temperatures (-78°C) under very strict control of reaction conditions; processes involving extreme low temperatures are undesirable for large-scale operations since they require special equipment and an additional reactor, adding to the cost, thereby making the processes commercially unfeasible.
Various processes for the preparation of Linezolid, its intermediates, and related compounds are described in U.S. Patent Nos. US 5,837,870, US 5,880,118, US 6,107,519, US 6,362,334, US 6,887,995, US 7,429,661, US 7,307,163 and US 7,291,614; PCT
Publication Nos. WO 99/24393, WO 2007/116284, WO 2009/063505, WO 2010/031769, WO 2010/081404, WO 2010/084514, WO 2011/077,310, WO 2011/137222 and WO 2012/114355; Chinese Patent Application Publication No. CN 1772750; and Journal Articles: J. Med. Chem. 39(3), 673-679, 1996; Tetrahedron Lett., 40(26), 4855, 1999; and Organic Letters 2003, 5, 963-965.
According to the U.S. Patent No. 5,837,870 (hereinafter referred to as the US'870 patent), the Linezolid is prepared by a process as depicted in scheme 2:
Scheme-2:
THF
t-amylalcohol
2 BuLi/hexane
(S)-(+)-3-chloro- uoro- 1 ,2-propanediol
Triethylamine/
methylenechloride
4-Nitrobenzene
(R)-[N-3-(3-Fluoro-4-(4-morpholinyl sulfonylchloride (R)-[N-3-[3-Fluoro-4-morpholinylphenyl]- phenyl)-2-oxo-5-oxazolidinyl] 2-oxo-5-oxazazolidinyl]-methanol 4-nitro methanol benzenesulfonate ester
salicylaldehyde imine
As stated in the preceding paragraphs, the processes for the preparation of Linezolid as disclosed in the prior art were tedious and cumbersome - for example, U.S. Patent No. 5,837,870 describes a process for the preparation of (5R)-5-(hydroxymethyl)-3- [3-fluoro-4-(4-morpholinyl)phenyl]-2-oxazolidinone intermediate wherein, tetrahydrofuran is mixed with t-amyl alcohol, followed by the addition of butyl lithium in hexanes with agitation to produce a lithium t-amylate mixture, which is then added to solution of N- carbobenzyloxy-3-fluoro-4-morpholinyl aniline [obtained as per the process described in J. Med. Chem., 39(3), 673 (1996)] in tetrahydrofuran while maintaining the temperature at less than 8°C and rinsed in with tetrahydrofuran to produce a lithium anion mixture.
Tetrahydrofuran is mixed with S-(+)-3-chloro-l,2-propanediol, the resulting mixture is cooled to -16°C, followed by the addition of potassium t-butoxide in tetrahydrofuran while maintaining the temperature at less than -10°C. The resulting slurry is then stirred at - 14°C to 0°C for 1 hour and then added to the lithium anion mixture while maintaining both mixtures at 0°C, then rinsed in with tetrahydrofuran. The resulting slurry is stirred for 2 hours at 20-23 °C and then cooled to 6°C, followed by the addition of a mixture of citric acid monohydrate in water. The resultant liquid phases are separated and the lower aqueous phase is washed with ethyl acetate. The organic layers are combined and solvent is removed under reduced pressure. Heptane and water are added to the resulting mass and the solvent is removed by reduced pressure until a total volume of 5 ml remains. The precipitated product is collected by vacuum filtration and washed with water and then dried in a stream of nitrogen to produce (5 )-5-(hydroxymethyl)-3-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxazolidinone.
Organic Letters 2003, 5, 963-965 describes a process for the preparation of Linezolid as depicted in scheme 3:
(R)-[N-3-(3-Fluoro-4-(4-morpriolinyl (R)-[N-3-(3-Fluoro-4-(4-morpholinyl
phenyl)-5-(tetrahydropyran-2-yloxy phenyl)-2-oxo-5-oxazolidinyl]
meth l)-oxazolidin-2-one methanol
Linezolid
(R)-[N-3-(3-Fluoro-4-morpholinyl
phenyl)-2-oxo-5-oxazolidinyl]
methylazide
U.S. Patent No. 6,107,519 (hereinafter referred to as the US'519 patent) describes various processes for the preparation of Linezolid as depicted in schemes 4 & 5:
Sc eme-4:
Triethylamine
(S)-1 -Acetamido-2-hydroxy- 3-Fluoro-4-morpholinyl 3-Fluoro-4-morpholinyl 3-chloropropane phenylisocyanate aniline
Pentanol
Heptane
Ethanol
Scheme-5:
(S
Methyl chloroformate
Lithium tert-butoxide
Linezolid Potassium carbonate
-78°C
N-Carbomethoxy-3-fluoro-4- moφholinyl aniline
PCT Publication No. WO 2012/114355 describes a process for the preparation of Linezolid as depicted in scheme 6:
Scheme 6:
ro
(5R)-[[3-[3-Fluoro- -(4-morpholinyl)]
phenyl]-2-oxo-5-oxazolidinyl]methyl (5R)-5-(Hydroxymethyl)-3-[3-fluoro-4- acetate morpholinyl)phenyl]-2-oxazolidinone
(R)-N-[(3-[3-Fluoro-4-rnorpholinyl]phenyl] (S)-N-[[3-[3-Fluoro-4-morpholinyl]
-2-oxo-5-oxazazolidinyl]-methyl phenyl]-2-oxo-5-oxazolidinyl]methyl]- methanesulfonate
(S)-N-[3-Fluoro-4-(4-morpholinyl)
phenyl]-2-oxo-5-oxazolidinyl]methyl Linezolid
amine
The processes for the preparation of Linezolid as described in the aforementioned prior art suffer from the following disadvantages and limitations:
a) the prior art processes involve the use of highly flammable and dangerous reagents like n-butyl lithium in hexanes;
b) handling of n-butyl lithium is very difficult at lab scale and in commercial scale operations;
c) the reaction between N-carbobenzyloxy-3-fluoro-4-morpholinyl aniline and (R)- glycidyl butyrate in tetrahydrofuran in the presence of n-butyl lithium/hexane should
be performed at extremely low temperatures (-78°C to -16°C) under very strict control of reaction conditions; processes involving extremely low temperatures are undesirable for large-scale operations since they require special equipment and an additional reactor, adding to the cost, thereby making the processes commercially unfeasible; d) the processes require longer reaction times and the yields and purity of the product obtained is very low;
e) the processes involve the use of expensive reagents including noble metal catalysts such as palladium on charcoal; and expensive chiral reagents such as (±)-trans-l,2- diaminocyclohexane, in excess amounts, for preparing the starting material 5- (tetrahydro-pyran-2-yloxymethyl)-2-oxazolidinone which is difficult to synthesize; f) the processes involve the use of tedious and cumbersome procedures like prolonged reaction time periods, multiple process steps, column chromatographic purifications, multiple isolation /re-crystallizations - methods involving column chromatographic purifications are generally undesirable for large-scale operations, thereby making the process commercially unfeasible;
g) the processes involve the use of multiple and excess amounts of hazardous solvents like n-hexane, heptanes, dioxane and tetrahydrofuran;
h) the processes involve the use of highly toxic reagents like phosgene, triphosgene, pyridinium p-toluenesulfonate, pyridine and sodium azide;
i) methods involving column chromatographic purifications are generally undesirable for large-scale operations, thereby making the process commercially unfeasible;
j) the overall processes generate a large quantity of chemical waste which is difficult to treat.
The major drawback of the processes for the preparation of linezolid described in the aforementioned prior art is that the processes involve the use of highly flammable, corrosive and pyrophoric reagents like n-butyl lithium in hexanes, thereby requiring very strict control of reaction conditions at low temperatures (-78°C to -16°C). Handling of n- butyl lithium is very difficult at lab scale and in commercial scale operations. Moreover, the yields and purities of the product obtained according to the prior art processes are very low.
Based on the aforementioned drawbacks, the prior art processes have been found to be unsuitable for the preparation of (5R)-5-(hydroxymethyl)-3-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxazolidinone at lab scale and in commercial scale operations.
U.S. Patent No. 7,307,163 B2 (hereinafter referred to as the US'163 patent), assigned to Symed Labs Limited (the present applicant), discloses a novel and commercially viable process for the preparation of Linezolid as depicted in scheme 7:
Scheme-7:
3-Fluoro-4-morpholinyl
aniline
N-[3-Chloro-2-(R)-hydroxypropyl]
-fluoro- -morpholinyl aniline
(S)-N-[[3-[3-Fluoro-4-[4-morpholinyl] -2-oxazolidinone phenyl-2-oxo-5-oxazolidinyl]methyl]
thalimide
phenyl-2-oxo-5-oxazolidinyl]methyl]
amine Linezolid
U.S. Patent No. 7,429,661 B2 (hereinafter referred to as the US'661 patent), assigned to Symed Labs Limited (the present applicant), discloses a novel and commercially viable process for the preparation of Linezolid as depicted in scheme 8:
Scheme-8:
N-[3-Chloro-2-(R)-hydroxypropyl]-3- Potassium phthalim
fluoro-4-morpholinyl aniline
3-Fluoro-4-morpholinyl
aniline (S)-N-2,3-epoxypropyl
hthalimide
Hydrazine hydrate/
Aq. Methylamine
Linezolid
(S)-N-[3-Fluoro-4-(4-morpholinyl) (S)-N-[[3-[3-Fluoro-4-[4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] phenyl-2-oxo-5-oxazolidinyl]methyl] methylamine phthalimide
However, a need remains for an improved, commercially viable, cost effective and environmentally friendly process of preparing Linezolid with high yield and purity, to resolve the problems associated with the processes described in the prior art, and that will be suitable for large-scale preparation. Desirable process properties include non-hazardous conditions, environmentally friendly and easy to handle reagents, reduced cost, greater simplicity, increased purity, and increased yield of the product, thereby enabling the production of Linezolid, in high purity and with high yield.
SUMMARY OF THE INVENTION
The present inventors have surprisingly and unexpectedly found that Linezolid can be prepared in high purity and with high yield, by reacting N-[3-phthalimido-2-(R)- hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline with an alkyl or aryl chloroformate, or a dicarbonate reagent, in the presence of a base to produce an alkyl/aryl N-[3-phthalimido-2- (R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamate intermediate, which is then reacted with an acetylating agent to produce an alkyl/aryl N-[3-phthalimido-2-(R)-
acetyloxypropyl]- -[3-fluoro-4-(4-mo holinyl) henyl]-caΓbanlate, followed by deprotection with a suitable reagent in the presence of a base to produce linezolid.
In one aspect, provided herein are efficient, industrially advantageous and environmentally friendly processes for the preparation of linezolid, in high yield and with high purity, using novel intermediates. The processes disclosed herein avoid the tedious and cumbersome procedures of the prior processes, thereby resolving the problems associated with the processes described in the prior art, which is more convenient to operate at lab scale and in commercial scale operations.
In another aspect, provided herein is a novel (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
In another aspect, provided herein is a novel (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
In another aspect, provided herein is a novel (R)-amino-2-acetyloxypropyl- carbamate compound of formula V:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is Ci-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
In another aspect, provided herein is a novel (R)-arnino-2-hydroxypropyl- carbamate compound of formula VI:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
In another aspect, provided herein is a novel (R)-2-hydroxypropyl-carbamate compound of formula VII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and Y is a leaving group such as a halogen or a sulfonyloxy group.
In another aspect, provided herein is a novel (R)-2-acetyloxypropyl-carbamate compound of formula VIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; Y is a leaving group such as a halogen or a sulfonyloxy group, and 'Ac' represents an acetyl group.
In another aspect, provided herein is a novel (R)-2,3-epoxypropyl-carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
In another aspect, provided herein is a novel N-[2(R)-2,3-epoxypropyl]-3-fluoro-4- (4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
In another aspect, provided herein is a novel (R)-acetamido-2-hydroxypropyl- carbamate compound of formula XI:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is CM2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
In another aspect, provided herein is a novel (R)-acetamido-2-acetyloxypropyl- carbamate compound of formula XII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1 -12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
In another aspect, the present invention also encompasses the use of the novel compounds of formula III, IV, V, VI, VII, VIII, IX, X, XI and XII disclosed herein for preparing Linezolid.
The processes for the preparation of Linezolid disclosed herein have the following advantages over the processes described in the prior art:
i) the processes involve the use of novel intermediate compounds;
ii) the overall process involves a reduced number of process steps, shorter reactions times and less expensive reagents thereby making the process cost effective;
iii) the overall yield of the Linezolid product is increased and the purity of the product is increased without additional purifications such as multiple isolations and re- crystallizations or column chromatographic purifications;
iv) the processes avoid the use of highly inflammable, dangerous and difficult to handle reagents like n-butyl lithium;
v) the processes avoid the use of highly inflammable and toxic solvents like hexane, dioxane and heptanes;
vi) the processes avoid the use of additional and excess amounts of solvents, multiple isolation steps, column chromatographic purifications;
vii)the processes avoid the use of expensive reagents including noble metal catalysts, e.g., palladium on charcoal, chiral reagents like (±)-trans-l,2-diaminocyclohexane and 5- (tetrahydro-pyran-2-yloxymethyl)-2-oxazolidinone;
viii) the process avoids the use of tedious and cumbersome procedures like prolonged reaction time periods, extremely low temperatures (-78°C to -16°C), multiple process steps, column chromatographic purifications, multiple isolations, additional and excess amounts of solvents; and
ix) the process involves easy work-up methods and simple isolation processes, and there is a reduction in chemical waste.
In a preferred embodiment, the radical R\ in the compounds of formulae III, IV, V, VI, VII, VIII, IX, XI and XII is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
In another preferred embodiment, the leaving group Y in the compound of formula VII & VIII is a halogen, or an alkyl or aryl sulfonyloxy group. Specifically, the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
The processes for the preparation of Linezolid using novel intermediates disclosed herein may be represented by a schematic diagram as depicted in scheme-9:
According to one aspect, there is provided an improved and cost effective process the preparation of Linezolid of formula I:
an enantiomeric form or a mixture of enantiomeric forms thereof, which comprises: acetylating (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is CM 2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl;
with an acetylating agent optionally in the presence of a base to produce an (R)- phthalimido-2-acetyloxypropyl-carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is as defined in formula IV, and 'Ac' represents an acetyl group; and
reacting the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III with a suitable reagent, optionally in the presence of a base, to produce the Linezolid of formula I.
The structural formulae of novel intermediate compounds disclosed herein contain one chiral centre and thus exist as two optical isomers, i.e. enantiomers (R & S-isomers). The process disclosed herein encompasses the preparation of both enantiomers and mixtures thereof in all proportions.
In one embodiment, the radical Ri in the compounds of formulae III and IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
Unless otherwise specified, the term "alkyl", as used herein, denotes an aliphatic hydrocarbon group which may be straight or branched having 1 to 12 carbon atoms in the chain. Preferred alkyl groups have 1 to 6 carbon atoms in the chain. The alkyl may be substituted with one or more "cycloalkyl groups". Exemplary alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n- butyl, iso-butyl, t-butyl, and n-pentyl.
The term "cycloalkyl", as used herein, denotes a non-aromatic mono- or multicyclic ring system of 3 to 10 carbon atoms, preferably of about 5 to about 10 carbon atoms. Exemplary monocyclic cycloalkyl groups include cyclopentyl, cyclohexyl, cycloheptyl and the like.
The term "aralkyl", as used herein, denotes an aryl-alkyl group wherein the aryl and alkyl are as herein described. Preferred aralkyls contain a lower alkyl moiety. Exemplary aralkyl groups include benzyl, 2-phenethyl and naphthalenemethyl.
The term "aryl", as used herein, denotes an aromatic monocyclic or multicyclic ring system of 6 to 10 carbon atoms. The aryl is optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Exemplary aryl groups include phenyl, tolyl or naphthyl.
The compounds of formulae III & IV disclosed herein are novel and constitute another aspect of the present invention.
The use of the novel intermediate compounds of formulae III & IV in the preparation of Linezolid of formula I is novel and forms further aspect of the present invention.
Advantageously, the novel intermediate compounds of Linezolid disclosed herein are obtained as solid state forms in substantially pure form.
The term "substantially pure" as used herein refers to the solid state form of linezolid intermediates, disclosed herein, having a purity of greater than about 90 wt%, specifically greater than about 95 wt%, more specifically greater than about 98 wt%, and still more specifically greater than about 99 wt%. The purity is preferably measured by High Performance Liquid Chromatography (HPLC). For example, the purity of solid state form of linezolid intermediates obtained by the processes disclosed herein can be about 95% to about 99%, or about 98% to about 99.9%, as measured by HPLC.
Unless otherwise specified, the term 'salt' as used herein may include acid addition salts and base addition salts.
Acid addition salts, as used herein, include the salts that are derived from organic and inorganic acids. For example, the acid addition salts are derived from a therapeutically acceptable acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, oxalic acid, acetic acid, propionic acid, phosphoric acid, succinic acid, maleic acid, fumaric acid, citric acid, glutaric acid, tartaric acid, benzenesulfonic acid, toluenesulfonic acid, di- p-toluoyl-L-(+)-tartaric acid, malic acid, ascorbic acid, and the like.
Base addition salts may be derived from an organic or an inorganic base. For example, the base addition salts are derived from alkali or alkaline earth metals such as sodium, calcium, potassium and magnesium; ammonium salt, organic amines such as ethylamine, tert-butylamine, diethylamine, diisopropylamine, and the like.
Exemplary acetylating agents used in step-(a) include, but are not limited to, acetyl halide such as acetyl chloride, acetyl bromide, acetyl iodide; acetic anhydride, sodium acetate, and the like, or a combination thereof. A most specific acetylating agent is acetic anhydride.
The reaction in step-(a) can be carried out in the presence or absence of a reaction inert solvent. In one embodiment, the reaction in step-(a) is carried out in the absence of a solvent. In another embodiment, the reaction in step-(a) is optionally carried out in the presence of a first solvent. The term solvent also includes mixture of solvents.
Exemplary first solvents used in step-(a) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
Specifically, the first solvent used in step-(a) is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n-hexane, n- heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl-tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specific first solvents are methanol, ethanol, isopropanol, and mixtures thereof.
In one embodiment, the acetylating agent in step-(a) is used in a ratio of about 1 to 6 equivalents, specifically about 3 to 5 equivalents, with respect to (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV in order to ensure a proper course of the reaction.
In another embodiment, the acetylation in step-(a) is optionally carried out in the presence of a base. Specifically, the base is an organic base or inorganic base, and most specifically an inorganic base.
Exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates, phosphates and carbonates of alkali or alkaline earth metals; ammonia, collidine, trimethylamine, triethylamine, tributylamine, diisopropylethylamine, N- methylmorpholine, 1-alkylimidazole and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Specific bases are aqueous ammonia, potassium phosphate, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide, potassium tert-butoxide, or a combination thereof; and most specifically potassium carbonate, sodium hydroxide and potassium hydroxide.
The reaction temperature and time period will ordinarily depend on the starting compounds and the solvent/reagent employed in the reaction.
In one embodiment, the acetylation reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 25°C to the reflux temperature of the solvent used, and more specifically at about 30°C to about 60°C. The reaction time may vary between about 1
hour to about 10 hours, specifically about 2 hours to about 7 hours, and more specifically about 4 hours to about 6 hours.
The reaction mass containing the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III obtained in step-(a) may be subjected to usual work up such as a washing, an extraction, a pH adjustment, an evaporation, a layer separation, a decolonization, or a combination thereof. The reaction mass may be used directly in the next step to produce the Linezolid of formula I, or the compound of formula III may be isolated and/or recrystallized and then used in the next step. After completion of the reaction, the excess acetic anhydride may be removed by distillation.
In one embodiment, the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III is isolated and/or re-crystallized from a suitable solvent by conventional methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, evaporation, vacuum distillation, or a combination thereof.
The solvent used for isolating and/or recrystallizing the (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III is selected from the group consisting of water, an alcohol, a ketone, an ether, an ester, a hydrocarbon solvent, a halogenated hydrocarbon, and mixtures thereof. Specifically, the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, tetrahydrofuran, 2-methyl-tetrahydrofuran, diisopropyl ether, methyl tert-butyl ether, ethyl acetate, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, dichloromethane, dichloroethane, chloroform, and mixtures thereof.
In one embodiment, a most specific (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III prepared by the process described herein is N-[3-phthalimido-2- (R)-acetyloxypropyl]-N-[3-fluoro-4-(4-moφholinyl) phenyl] -carbamic acid ethyl ester of formula Ilia (formula III, wherein Ri is ethyl):
In another embodiment, a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III prepared by the process described herein is N-[3- phthalimido-2-(R)-acetyloxyρropyl]-N-[3-fluoro-4-(4-mo holinyl) phenyl] -carbamic acid tert-butyl ester of formula Illb (formula III, wherein Ri is tert-butyl):
In another embodiment, a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III prepared by the process described herein is N-[3- phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl]-carbamic acid benzyl ester of formula IIIc (formula III, wherein Ri is benzyl):
The reagent used in step-(b) is a primary amine formation agent. Exemplary primary amine formation agents used in step-(b) include, but are not limited to, hydrazine hydrate, methyl amine, and the like. A most specific reagent is hydrazine hydrate or aqueous methyl amine.
In another embodiment, the reaction in step-(b) is optionally carried out in the presence of a base. Specifically, the base is an organic or inorganic base, and most specifically an inorganic base, selected from the group as described hereinabove.
Specific bases are aqueous ammonia, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate,
sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide and potassium tert-butoxide; and most specifically potassium carbonate.
In one embodiment, the reaction in step-(b) is carried out in the presence of a second solvent.
Exemplary second solvents used in step-(b) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
Specifically, the second solvent used in step-(b) is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n- hexane, n-heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl- tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, Ν,Ν-dimethylformamide, N,N- dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specific second solvents are methanol, ethanol, isopropanol, acetone, and mixtures thereof.
In one embodiment, the reagent in step-(b) is used in a ratio of about 1 to 5 equivalents, specifically about 3 to 5 equivalents, with respect to the (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III in order to ensure a proper course of the reaction.
In one embodiment, the reaction in step-(b) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used. The reaction time may vary between about 3 hours to about 10 hours, and specifically about 4 hours to about 6 hours.
The reaction mass containing the Linezolid of formula I obtained may be subjected to usual work up such as a washing, an extraction, an evaporation, a pH adjustment etc., followed by isolation and/or recrystallization from a suitable solvent by conventional methods such as cooling, seeding, partial removal of the solvent from the solution, by adding an anti-solvent to the solution, evaporation, vacuum distillation, or a combination thereof.
It has been found that two novel intermediate compounds, namely (R)-amino-2- acetyloxypropyl-carbamate compound of formula V and (R)-acetamido-2-hydroxypropyl- carbamate compound of formula XI, are formed when reacting the (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III with the primary amine formation agent and these novel compounds may be isolated using the methods described herein. The novel compounds of formula V and formula XI are characterized by having the following structural formulae:
Particular variations of reaction conditions and parameters (e.g., temperature, time, reagent, base, solvent, etc.) may permit the isolation of the compounds of formulae V and XI. For example, use of mild reaction conditions (e.g. low temperatures and mild base) may permit isolation of the compound of formula V. Application of heat to the compound of formula V optionally in the presence of a base may permit the isolation of the compound of formula XL In one embodiment, the reaction time may vary between about 30 minutes to about 10 hours and specifically about 1 hour to about 3 hours. The isolated novel intermediate compounds of formulae V and XI may be further converted into linezolid of formula I using the methods described herein.
The solvent used for washing, extracting, isolating and/or recrystallizing the pure Linezolid of formula I is selected from the group as described herein above. Specifically, the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, tetrahydrofuran, 2-memyl-tetrahydrofuran, diisopropyl ether, methyl tert-butyl ether, ethyl acetate, n-pentane, n-hexane, n-heptane, cyclohexane,
toluene, xylene, dichloromethane, dichloroethane, chloroform, and mixtures thereof. Most specifically, the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, ethyl acetate, dichloromethane, and mixtures thereof.
In one embodiment, the isolation is carried out by cooling the reaction mass at a temperature of below about 35°C, followed by the addition of water at a temperature of about 10°C to about 35°C, and more specifically at a temperature of about 20°C to about 30°C. After completion of addition process, the resulting mass is optionally stirred at a temperature of about 10°C to about 35°C for at least 10 minutes, and most specifically at a temperature of about 20°C to about 30°C for about 15 minutes to about 2 hours.
In another embodiment, the isolation is carried out by cooling the reaction mass while stirring at a temperature below about 30°C and more specifically at about 20°C to about 30°C.
The solid obtained is collected by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
The novel (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV employed as intermediate in the process for manufacture of Linezolid disclosed herein allows the product to be easily isolated and purified, thereby producing a product with 70- 80% overall yield.
According to another aspect, there is provided a process for the preparation of Linezolid of formula I, or an enantiomeric form or a mixture of enantiomeric forms thereof, comprising reacting the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is Ci-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group;
with a suitable reagent, optionally in the presence of a base, to produce the Linezolid of formula I.
In one embodiment, the radical Ri in the compounds of formula III is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
The process for the preparation of linezolid of formula I disclosed herein is carried out by using the methods, reagents and parameters as described hereinabove.
According to another aspect, there is provided a process for the preparation of (R)- phthalimido-2-acetyloxypropyl-carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C\.n straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group;
comprising acetylating (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula
IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is as defined above; with an acetylating agent optionally in the presence of a base to produce an
(R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III or an enantiomeric form or a mixture of enantiomeric forms thereof.
In one embodiment, the radical Ri in the compounds of formulae III & IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R] is methyl, ethyl, benzyl or tert-butyl.
The process for the preparation of (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III disclosed herein is carried out by using the methods, reagents and parameters as described hereinabove.
According to another aspect, there is provided an improved and cost effective process for the preparation of Linezolid of formula I, or an enantiomeric form or a mixture of enantiomeric forms thereof, which comprises:
a) reacting (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R] is C .n straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; with a suitable reagent, optionally in the presence of a base, to produce (S)-N-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl-methyl amine of formula II:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; and
b) acetylating the amine compound of formula II with a suitable acetylating agent to produce the Linezolid of formula I.
In one embodiment, the radical Rt in the compounds of formula IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
The reagent used in step-(a) is a primary amine formation agent. Exemplary primary amine formation agents used in step-(a) include, but are not limited to, hydrazine hydrate, methyl amine, and the like. A most specific reagent is hydrazine hydrate or aqueous methyl amine.
In another embodiment, the reaction in step-(a) is carried out in the presence of a base. Specifically, the base is an organic or inorganic base, and most specifically an inorganic base, selected from the group as described hereinabove.
Specific bases are aqueous ammonia, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide and potassium tert-butoxide; and most specifically potassium carbonate.
In one embodiment, the reaction in step-(a) is carried out in the presence of a solvent. Exemplary solvents used in step-(a) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
Specifically, the solvent used in step-(a) is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl-tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specifically, the solvent is selected from the group consisting of methanol, ethanol, isopropanol, acetone, and mixtures thereof.
In one embodiment, the reagent in step-(a) is used in a ratio of about 1 to 5 equivalents, specifically about 3 to 5 equivalents, with respect to the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV in order to ensure a proper course of the reaction.
In one embodiment, the reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used. The reaction time may vary between about 2 hours to about 8 hours, and specifically about 3 hours to about 4 hours.
The reaction mass containing the (S)-N-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo- 5-oxazolidinyl-methyl amine of formula II obtained in step-(a) may be subjected to usual work up methods as described hereinabove. The reaction mass may be used directly in the next step to produce the Linezolid of formula I, or the compound of formula II may be isolated and/or recrystallized and then used in the next step.
In one embodiment, the (S)-N-[3-fiuoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl-methyl amine of formula II is isolated and/or re-crystallized from a suitable solvent by the methods as described hereinabove.
It has been found that a novel intermediate compound, (R)-amino-2- hydroxypropyl-carbamate compound, of formula VI is formed when reacting the (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV with the primary amine formation agent and it may be isolated using the methods described herein. The novel compound of formula VI is characterized by having the following structural formula:
Particular variations of reaction conditions and parameters (e.g., temperature, time, reagent, base, solvent, etc.) may permit the isolation of the compound of formula VI. For example, use of mild reaction conditions (e.g. low temperatures and mild base) may permit isolation of the compound of formula VI. The isolated novel intermediate compound of
formulae VI may be further converted into linezolid of formula I using the methods described herein.
The solvent used for isolating and/or recrystallizing the (S)-N-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxo-5-oxazolidinyl-methyl amine of formula II is selected from the group as described above for such purpose. Specifically, the solvent is selected from the group consisting of water, methanol, ethanol, n-propanol, isopropyl alcohol, acetone, tetrahydrofuran, 2-methyl-tetrahydrofuran, diisopropyl ether, methyl tert-butyl ether, ethyl acetate, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, dichloromethane, dichloroethane, chloroform, and mixtures thereof.
The acetylation reaction in step-(b) is carried out by the methods known in the art.
Exemplary acetylating agents used in step-(b) include, but are not limited to, acetyl halide such as acetyl chloride, acetyl bromide, acetyl iodide; acetic anhydride, sodium acetate, and the like, or a combination thereof. A most specific acetylating agent is acetic anhydride.
The reaction mass containing the linezolid of formula I obtained in step-(b) may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent using the methods as described herein above.
According to another aspect, there is provided an improved process for the preparation of (S)-N-[3-fluoro-4-(4-mo holinyl)phenyl]-2-oxo-5-o azolidinyl-methyl amine of formula II:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or 'a salt thereof; comprising reacting (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula
IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; with a suitable reagent, optionally in the presence of a base, to produce the aminomethyl compound of formula II, or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
In one embodiment, the radical Rj in the compounds of formulae IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R\ is methyl, ethyl, benzyl or tert-butyl.
The process for the preparation of (S)-N-[3-fluoro-4-(4-morpholinyl)phenyl]-2- oxo-5-oxazolidinyl-methyl amine of formula II disclosed herein is carried out by using the methods, reagents and parameters as described hereinabove.
According to another aspect, there is provided a process for the preparation of (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; comprising reacting N-[3-phthalimido-2-(R)- hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof;
with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XlVb:
wherein the radical Ri is as defined in Formula IV; to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
In one embodiment, the radical Ri in the compounds of formulae IV, XlVa &
XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
Unless otherwise specified, the N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-
4-(4-morpholinyl)aniline of formula XIII as used herein as starting material is a known compound and can be obtained by the processes described in the prior art, for example, the processes described in the U.S. Patent No. 7,429,661 B2 assigned to Symed Labs Limited
(the present applicant).
In one embodiment, the reaction between the compounds of formula XIII and XlVa or XlVb is carried out in the presence of a base. Specifically, the base is an organic or inorganic base, and most specifically an organic base.
Exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates and carbonates of alkali or alkaline earth metals; ammonia, collidine, trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, and 1-alkylimidazole.
Specific bases are trimethylamine, tributylamine, triethylamine, diisopropylethylamine and N-methylmorpholine; and most specifically diisopropylethylamine.
In one embodiment, the reaction between the compounds of formula XIII and XlVa or XlVb is carried out in the presence of a solvent. Exemplary solvents used herein include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof. A most specific solvent is dichloromethane.
In one embodiment, the activating agent of formula XlVa or XlVb is used in a ratio of about 1 to 3 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the N- [3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-moφholinyl)aniline of formula XIII in order to ensure a proper course of the reaction.
In one embodiment, the reaction between the compounds of formula XIII and the activating agent is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 10°C to the reflux temperature of the solvent used, and most specifically at a temperature of about 20°C to about 40°C. The reaction time may vary between about 30 minutes to about 8 hours, specifically about 1 hour to about 5 hours, and more specifically about 1 hour to about 2 hours.
The reaction mass containing the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV obtained may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent using the methods as described herein above.
The solvent used for isolating and/or recrystallizing the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV is selected from the group as described herein above.
In one embodiment, a most specific (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV prepared by the process described herein is N-[3-phthalimido-2- (R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester of formula IVa (formula IV, wherein R\ is ethyl):
In another embodiment, a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV prepared by the process described herein is N-[3- phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-mo holinyl)phenyl]-carbamic acid tert-butyl ester of formula IVb (formula IV, wherein Ri is tert-butyl):
or an enantiomeric form or a mixture of enantiomeric forms thereof.
In another embodiment, a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV prepared by the process described herein is N-[3- phthalimido-2-(R)-hydroxypropyl] -N- [3 -fluoro-4-(4-morpholinyl)phenyl] -carbamic acid benzyl ester of formula IVc formula IV, wherein Rj is benzyl):
According to another aspect, there is provided a process for the preparation of (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is
straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl; which comprises:
reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3- epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group such as a halogen or a sulfonyloxy group;
with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XI Vb:
wherein the radical Ri is as defined in Formula IV; to produce an (R)-2- hydroxypropyl-carbamate compound of formula VII or an (R)-2,3-epoxypropyl- carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj and Y are as defined above; and
b) reacting the (R)-2-hydroxypropyl-carbamate compound of formula VII or the (R)-2,3- epoxypropyl-carbamate compound of formula IX obtained in step-(a) with potassium phthalimide, optionally in the presence of a base, to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
In one embodiment, the radical Ri in the compounds of formulae IV, VII, IX, XlVa & XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R\ is methyl, ethyl, benzyl or tert-butyl.
In another embodiment, the leaving group Y in the compounds of formulae VII and XV is a halogen, or an alkyl or aryl sulfonyloxy group. Specifically, the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
The compounds of formulae IV, VII, IX & X disclosed herein are novel and constitute another aspect of the present invention.
The use of the novel intermediate compounds of formulae IV, VII, IX & X in the preparation of Linezolid of formula I is novel and forms further aspect of the present invention.
Unless otherwise specified, the (R)-2-hydroxypropyl-aniline compound of formula XV as used herein as starting material is a known compound and can be obtained by the processes described in the prior art, for example, the processes described in the U.S. Patent No. 7,307,163 B2 assigned to Symed Labs Limited (the present applicant).
In one embodiment, the reaction in step-(a) is carried out in the presence of a base. Specifically, the base is an organic or inorganic base, and most specifically an organic base, selected from the group as described herein above.
Exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates and carbonates of alkali or alkaline earth metals; ammonia, collidine,
trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, and 1-alkylimidazole.
Specific bases are trimethylamine, tributylamine, triethylamine, diisopropylethylamine and N-methylmorpholine; and most specifically diisopropylethylamine.
In one embodiment, the reaction in step-(a) is carried out in the presence of a solvent. Exemplary solvents used herein include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof. A most specific solvent is dichloromethane.
In one embodiment, the activating agent of formula XlVa or XlVb is used in a ratio of about 1 to 3 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the (R)-2-hydroxypropyl-aniline compound of formula XV, or N-[2(R)-2,3-epoxypropyl]-3- fluoro-4-(4-morpholinyl)aniline of formula X, in order to ensure a proper course of the reaction.
In one embodiment, the reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 10°C to the reflux temperature of the solvent used, and most specifically at a temperature of about 20°C to about 40°C. The reaction time may vary between about 30 minutes to about 8 hours, specifically about 1 hour to about 5 hours, and more specifically about 1 hour to about 2 hours.
The reaction mass containing the (R)-2-hydroxypropyl-carbamate compound of formula VII or an (R)-2,3-epoxypropyl-carbamate compound of formula IX obtained in step-(a) may be subjected to usual work up such as a washing, an extraction, a pH adjustment, an evaporation, a layer separation, a decolorization, or a combination thereof. The reaction mass may be used directly in the next step to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV, or the compound of formula VII or IX may be isolated and/or recrystallized and then used in the next step.
In one embodiment, the (R)-2-hydroxypropyl-carbamate compound of formula VII or an (R)-2,3-epoxypropyl-carbamate compound of formula IX is isolated and/or re- crystallized from a suitable solvent by conventional methods such as cooling, seeding,
partial removal of the solvent from the solution, by adding an anti-solvent to the solution, evaporation, vacuum distillation, or a combination thereof.
The solvent used for isolating and/or recrystallizing the (R)-2-hydroxypropyl- carbamate compound of formula VII or an (R)-2,3-epoxypropyl-carbamate compound of formula IX is selected from the group as described herein above.
In another embodiment, the reaction in step-(b) is optionally carried out in the presence of a base. Specifically, the base is an organic or inorganic base selected from the group as described hereinabove.
In one embodiment, the reaction in step-(b) is carried out in the presence of a solvent. Exemplary solvents used in step-(b) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
Specifically, the solvent used in step-(b) is selected from the group acetonitrile, propionitrile, Ν,Ν-dimethylformamide, Ν,Ν-dimethylacetarnide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specific solvents are acetonitrile, N,N-dimethylformamide, and mixtures thereof.
In one embodiment, the potassium phthalimide in step-(b) is used in a ratio of about 1 to 2 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the (R)-2- hydroxypropyl-carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate Compound of formula IX in order to ensure a proper course of the reaction.
In one embodiment, the reaction in step-(b) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used. The reaction time may vary between about 1 hour to about 10 hours, and specifically about 4 hours to about 6 hours.
The reaction mass containing the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV obtained may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent by the methods as described herein above.
The solvent used for washing, extracting, isolating and/or recrystallizing the (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV is selected from the group as described herein above.
The solid obtained in step-(b) is collected by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
In one embodiment, a most specific (R)-2-hydroxypropyl-carbamate compound of formula VII prepared by the process described herein is N-[3-Chloro-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester of formula Vila (formula VII, wherein R\ is ethyl and Y is CI):
or an enantiomeric form or a mixture of enantiomeric forms thereof.
In another embodiment, a most specific (R)-2,3-epoxypropyl-carbamate compound of formula IX prepared by the process described herein is N-[2(R)-2,3-epoxypropyl]-N-[3- fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester of formula IXa (formula IX, wherein Ri is ethyl):
According to another aspect, there is provided a process for the preparation of (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; comprising reacting the (R)-2-hydroxypropyl- carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is as defined in Formula IV, and Y is a leaving group such as a halogen or a sulfonyloxy group; with potassium phthalimide, optionally in the presence of a base, to produce the (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
In one embodiment, the radical Ri in the compounds of formulae IV, VII & IX is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p- nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Ri is methyl, ethyl, benzyl or tert-butyl.
In one embodiment, the leaving group Y in the compound of formula VII is a halogen, or an alkyl or aryl sulfonyloxy group. Specifically, the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
The process for the preparation of (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV disclosed herein is carried out by using the methods, reagents and parameters as described hereinabove.
According to another aspect, there is provided a process for the preparation of (R)- 2-hydroxypropyl-carbamate compound of formula VII or the (R)-2,3-epoxypropyl- carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is CM2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl, and Y is a leaving group such as a halogen or a sulfonyloxy group; comprising reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group such as a halogen or a sulfonyloxy group;
with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula
XlVb:
(or)
wherein the radical R\ is as defined above; to produce the (R)-2-hydroxypropyl-carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate compound of formula IX or an enantiomeric form or a mixture of enantiomeric forms thereof.
In one embodiment, the radical Ri in the compounds of formulae VII, IX, XlVa &
XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically Rj is methyl, ethyl, benzyl or tert-butyl.
In one embodiment, the leaving group Y in the compound of formula VII & XV is a halogen, or an alkyl or aryl sulfonyloxy group. Specifically, the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and tnfluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
The process for the preparation of (R)-2-hydroxypropyl-carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate compound of formula IX disclosed herein is carried out by using the methods, reagents and parameters as described hereinabove.
According to another aspect, there is provided a process for the preparation of (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; which comprises:
a) reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3- epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group such as a halogen or a sulfonyloxy group;
with potassium phthalimide, optionally in the presence of a base, to produce N-[3- phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-mo holinyl)aniline of formula XIII:
b) reacting the N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XlVb:
(or)
wherein the radical R\ is as defined in Formula IV; to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
In one embodiment, the radical R\ in the compounds of formulae IV, XlVa &
XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R\ is methyl, ethyl, benzyl or tert-butyl.
In one embodiment, the leaving group Y in the compound of formula XV is a halogen, or an alkyl or aryl sulfonyloxy group. Specifically, the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; < more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
In another embodiment, the reaction in step-(a) is optionally carried out presence of a base. Specifically, the base is an organic or inorganic base selected from the group as described hereinabove.
In one embodiment, the reaction in step-(a) is carried out in the presence of a solvent. Exemplary solvents used in step-(a) include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
Specifically, the solvent used in step-(a) is selected from the group acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specific solvents are acetonitrile, Ν,Ν-dimethylformamide, and mixtures thereof.
In one embodiment, the potassium phthalimide in step-(a) is used in a ratio of about
1 to 2 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to (R)-2-
hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3-epoxypropyl]-3-fluoro-4- (4-morpholinyl)aniline of formula X in order to ensure a proper course of the reaction.
In one embodiment, the reaction in step-(a) is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 20°C to the reflux temperature of the solvent used, and most specifically at the reflux temperature of the solvent used. The reaction time may vary between about 1 hour to about 10 hours, and specifically about 3 hours to about 6 hours.
The reaction mass containing the N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro- 4-(4-morpholinyl)aniline of formula XIII obtained in step-(a) may be subjected to usual work up such as a washing, an extraction, a pH adjustment, an evaporation, a layer separation, a decolorization, or a combination thereof. The reaction mass may be used directly in the next step to produce the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV, or the compound of formula XIII may be isolated and/or recrystallized and then used in the next step.
In one embodiment, the N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4- morpholinyl)aniline of formula XIII is isolated and/or re-crystallized from a suitable solvent by the methods described herein above.
The solvent used for isolating and/or recrystallizing the N-[3-phthalimido-2-(R)- hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII is selected from the group as described herein above.
In one embodiment, the reaction in step-(b) is carried out in the presence of a base. Specifically, the base is an organic or inorganic base, and most specifically an organic base, selected from the group as described herein above.
Specific bases are trimethylamine, tributylamine, triethylamine, diisopropylethylamine and N-methylmorpholine; and most specifically diisopropy lethylamine .
In one embodiment, the reaction in step-(b) is carried out in the presence of a solvent. Exemplary solvents used herein include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof. A most specific solvent is dichloromethane.
In one embodiment, the activating agent of formula XlVa or XlVb is used in a ratio of about 1 to 3 equivalents, specifically about 1.1 to 1.5 equivalents, with respect to the N- [3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-mo holinyl)aniline of formula XIII in order to ensure a proper course of the reaction.
In one embodiment, the reaction in step-(b) is carried out at a temperature of about
0°C to the reflux temperature of the solvent used, specifically at a temperature of about 10°C to the reflux temperature of the solvent used, and most specifically at a temperature of about 20°C to about 40°C. The reaction time may vary between about 30 minutes to about 8 hours, specifically about 1 hour to about 5 hours, and more specifically about 1 hour to about 2 hours.
The reaction mass containing the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV obtained may be subjected to usual work up, followed by isolation and/or recrystallization from a suitable solvent by the methods as described herein above.
According to another aspect, there is provided a process for the preparation of N-
[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; comprising reacting N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, with potassium phthalimide, optionally in the presence of a base, to produce N-[3-phthalimido-
2-(R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
The process for the preparation of N-[3-phthalimido-2-(R)-hydroxypropyl]-3- fluoro-4-(4-morpholinyl)aniline of formula XIII disclosed herein is carried out by using the methods, reagents and parameters as described hereinabove.
According to another aspect, there is provided a process for the preparation of N- [2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; comprising reacting (R)-2-hydroxypropyl-aniline compound of formula XV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group such as a halogen or a sulfonyloxy group; with a base to produce the N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-mo holinyl)aniline of formula X or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
In one embodiment, the leaving group Y in the compound of formula XV is a halogen, or an alkyl or aryl sulfonyloxy group. Specifically, the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
In one embodiment, the base is an organic or inorganic base, and most specifically an inorganic base.
Exemplary bases include, but are not limited to, hydroxides, alkoxides, bicarbonates and carbonates of alkali or alkaline earth metals; ammonia, collidine, trimethylamine, tnbutylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, and 1-alkylimidazole.
Specific bases are aqueous ammonia, potassium phosphate, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide, potassium tert-butoxide, or a combination thereof; and most specifically potassium carbonate, sodium hydroxide and potassium hydroxide.
In one embodiment, the reaction between the (R)-2-hydroxypropyl-aniline compound of formula XV and the base is carried out in the presence of a solvent.
Exemplary solvents used herein include, but are not limited to, water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
Specifically, the solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate, ethyl formate, acetone, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl-tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof. Most specific solvents are water, dichloromethane, and mixture thereof.
In one embodiment, the reaction between the (R)-2-hydroxypropyl-aniline compound of formula XV and the base is carried out at a temperature of about 0°C to the reflux temperature of the solvent used, specifically at a temperature of about 10°C to the reflux temperature of the solvent used, and most specifically at a temperature of about 20°C to about 40°C. The reaction time may vary between about 1 to about 16 hours, specifically about 6 hour to about 15 hours, and more specifically about 12 hours to about 14 hours.
The reaction mass containing the of N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4- morpholinyl)aniline of formula X obtained may be subjected to usual work up, followed
by isolation and/or recrystallization from a suitable solvent using the methods as described herein above.
The solids obtained in any of the above process steps described hereinabove may be collected by filtration, filtration under vacuum, decantation, centrifugation, filtration employing a filtration media of a silica gel or celite, or a combination thereof.
Aptly the processes of the invention are adapted to the preparation of oxazolidinone derivatives, preferably Linezolid, in high enantiomeric and chemical purity.
The novel intermediate compounds of formulae III, IV, V, VI, VII, VIII, IX, X, XI and XII employed for the preparation of linezolid disclosed herein allows the product to be easily isolated and purified, thereby producing a product with 60-80% overall yield.
The highly pure linezolid obtained by the above processes may be further dried in, for example, a Vacuum Tray Dryer, a Rotocon Vacuum Dryer, a Vacuum Paddle Dryer or a pilot plant Rota vapor, to further lower residual solvents. Drying can be carried out under reduced pressure until the residual solvent content reduces to the desired amount such as an amount that is within the limits given by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ("ICH") guidelines.
In one embodiment, the drying is carried out at atmospheric pressure or reduced pressures, such as below about 200 mm Hg, or below about 50 mm Hg, at temperatures such as about 35°C to about 90°C, and specifically at about 75°C to about 85°C. The drying can be carried out for any desired time period that achieves the desired result, such as times about 1 to 20 hours. Drying may also be carried out for shorter or longer periods of time depending on the product specifications. Temperatures and pressures will be chosen based on the volatility of the solvent being used and the foregoing should be considered as only a general guidance. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer, and the like.
In another embodiment, the highly pure linezolid obtained by the processes disclosed herein has a total purity, includes both chemical and enantiomeric purity, of greater than about 99%, specifically greater than about 99.5%, more specifically greater than about 99.9%, and most specifically greater than about 99.95% as measured by HPLC.
According to another aspect, there is provided a novel (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
In one embodiment, a most specific (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III disclosed herein is N-[3-phthalimido-2-(R)-acetyloxypropyl]-N- [3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid ethyl ester of formula Ilia (formula III, wherein R\ is ethyl):
In another embodiment, a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III disclosed herein is N-[3-phthalimido-2-(R)- acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid tert-butyl ester of formula Illb (formula III, wherein Ri is tert-butyl):
or an enantiomeric form or a mixture of enantiomeric forms thereof.
In another embodiment, a most specific (R)-phthalimido-2-acetyloxypropyl- carbamate compound of formula III disclosed herein is N-[3-phthalimido-2-(R)- acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid benzyl ester of formula IIIc (formula III, wherein R\ is benzyl):
According to another aspect, there is provided a novel (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is CM2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
In one embodiment, a most specific (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV disclosed herein is N-[3-phthalimido-2-(R)-hydroxypropyl]-N-
[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester of formula IVa (formula IV, wherein Ri is ethyl):
or an enantiomeric form or a mixture of enantiomeric forms thereof.
In another embodiment, a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV disclosed herein is N-[3-phthalimido-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-mo holinyl)phenyl]-carbamic acid tert-butyl ester of formula IVb (formula IV, wherein R\ is tert-butyl):
or an enantiomeric form or a mixture of enantiomeric forms thereof.
In another embodiment, a most specific (R)-phthalimido-2-hydroxypropyl- carbamate compound of formula IV disclosed herein is N-[3-phthalimido-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid benzyl ester of formula IVc (formula IV, wherein Rj is benzyl):
According to another aspect, there is provided a novel (R)-amino-2- acetyloxypropyl-carbamate compound of formula V:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is Ci straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
According to another aspect, there is provided a novel (R)-amino-2-hydroxypropyl- carbamate compound of formula VI:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
According to another aspect, there is provided a novel (R)-2-hydroxypropyl- carbamate compound of formula VII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C .n straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and Y is a leaving group such as a halogen or a sulfonyloxy group.
According to another aspect, there is provided a novel (R)-2-acetyloxypropyl- carbamate compound of formula VIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C\ straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl; Y is a leaving group such as a halogen or a sulfonyloxy group, and 'Ac' represents an acetyl group.
According to another aspect, there is provided a novel (R)-2,3-epoxypropyl- carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1.12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
According to another aspect, there is provided a novel N-[2(R)-2,3-epoxypropyl]-3- fluoro-4-(4-morpholinyl)aniline of formula X:
According to another aspect, there is provided a novel (R)-acetamido-2- hydroxypropyl-carbamate compound of formula XI:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C\ straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl.
According to another aspect, there is provided a novel (R)-acetamido-2- acetyloxypropyl-carbamate compound of formula XII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
In a preferred embodiment, the radical in the compounds of formulae III, IV, V, VI, VII, VIII, IX, XI and XII is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, olyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and most specifically R is methyl, ethyl, benzyl or tert-butyl.
In another embodiment, the leaving group Y in the compound of formulae VII & VIII is a halogen, or an alkyl or aryl sulfonyloxy group. Specifically, the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; more specifically the leaving group Y is CI or toluenesulfonyloxy; and a most specific leaving group is CI.
According to another aspect, the present invention also encompasses the use of the novel compounds of formulae III, IV, V, VI, VII, VIII, IX, X, XI and XII disclosed herein for preparing Linezolid. INSTRUMENTAL DETAILS:
HPLC Method for measuring Chemical Purity:
The chemical purity was measured by HPLC using Shimadzu LC-2010 CHT system with LC solutions software or its equivalent under the following conditions: Column = Kromasil 100 CI 8, 250 mm x 4.6 mm, 5μιη or Equivalent; Detector wavelength = 254 nm; Flow Rate = 0.5 ml/minute; Injection volume = 20μί; Oven temperature = 40°C; Run time
= 30 minutes; Diluent = Acetonitrile; Elution = Isocratic; Mobile Phase = Water (400 ml) : acetonitrile (600 ml) : triethyl amine (1.8 ml) : acetic acid (1.3 ml).
The following examples are given for the purpose of illustrating the present invention and should not be considered as limitation on the scope or spirit of the invention.
EXAMPLES
Example 1
Preparation of N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide (Linezolid)
Step-1: N-[3-Phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid ethyl ester
Acetic anhydride (51 g, 0.5 moles) was added to N-[3-phthalimido-2-(R)-hydroxypropyl]- N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester and the contents were heated to 50-55°C, followed by maintaining the reaction mixture at the same temperature for 4 to 6 hours. After completion of the reaction, the resulting mass was distilled, to remove the excess acetic anhydride, to produce 47.2 g of N-[3-phthalimido-2-(R)- acetyloxypropyl]-N-[3-fluoro-4-(4-morpholinyl) phenyl] -carbamic acid ethyl ester, which is directly used in the next reaction step (Yield: 92%; Purity by HPLC: 98.2%).
Mass (m/z): 514 (M+l).
Step-2: Preparation of Linezolid
Potassium carbonate (12.7 g, 0.092 mol) and hydrazine hydrate (13.8 g, 0.276 mol) were added to a solution of N-[3-phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4-(4- morpholinyl) phenyl] -carbamic acid ethyl ester (47.2 g, 0.092 mol) in methanol (200 ml) and the mixture was heated to reflux, followed by maintaining the resulting mass at reflux temperature for 4 to 6 hours. After completion of the reaction, the solvent was distilled off completely, water (250 ml) was added to the resulting mass and then extracted with methyl chloride (150 ml x 3). The resulting organic layer was washed with water (100 ml x 3) and then concentrated to obtain crude product. Ethyl acetate (100 ml) was added to the resulting crude product and then stirred for 1 hour at 25-30°C. The separated solid was
filtered and then dried at 70-75°C to produce 25 g of pure Linezolid as a white crystalline solid (Yield: 81%; Purity by HPLC: 99.8%).
Example 2
Preparation of Linezolid
Potassium carbonate (12.7 g, 0.092 mol) and 40% monomethyl amine (28.5 g, 0.37 mol) were added to a solution of N-[3-phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4-(4- morpholinyl) phenyl] -carbamic acid ethyl ester (47.2 g, 0.092 mol) in methanol (200 ml) and the mixture was heated to reflux, followed by maintaining the resulting mass at reflux temperature for 4 to 6 hours. After completion of the reaction, the reaction mass was cooled to room temperature (25-30°C), followed by the addition of water (200 ml) and then stirring the mass for 1 hour at the same temperature. The separated solid was filtered, washed with methanol (50 ml) and then dried at 70-75°C to produce 26.7 g of pure Linezolid as a white crystalline solid (Yield: 86%; Purity by HPLC: 99.9%).
Example 3
Preparation of (S)-N-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl- methylamine
Step-1 : N-[3-Phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)
phenyl]-carbamic acid ethyl ester
N-Ethyldiisopropyl amine (16 g, 0.124 mol) was added to a suspension of N-[3- phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline (39.9 g, 0.1 mol) in methylene chloride (360 ml) at 25-30°C. Ethyl chloroformate (12 g, 0.11 mol) was slowly added to the resulting solution at 25-30°C during the time period of about 30 minutes, followed by stirring the mass at the same temperature for 1 to 2 hours. The reaction mass was washed subsequently with 4N hydrochloric acid solution (100 ml), water (100 ml) and saturated brine solution (100 ml) and then concentrated the resulting mass to produce 45 g of N- [3 -phthalimido-2-(R)-hydroxypropyl] -N- [3 -fluoro-4-(4-morpholinyl)phenyl] - carbamic acid ethyl ester as a residue (Yield: 95.5%; Purity by HPLC: 98.5%).
Mass (m/z): 472 (M+l).
Step-2: (S)-N-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl-methylamine
Potassium carbonate (13.8 g, 0.1 mol) and hydrazine hydrate (80%) (18.75 g, 0.3 mol) were added to a solution of N-[3-phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4- morpholinyl) phenyl] -carbamic acid ethyl ester (47.1 g, 0.1 mol) in methanol (280 ml) and the mixture was heated to reflux, followed by maintaining the resulting mass at reflux for 2 to 4 hours. After completion of the reaction, the solvent was distilled off completely and the resulting crude product was taken in ethylene chloride (200 ml) and the resulting organic layer was washed water (100 ml x 3) and then the solvent was distilled off to produce 24.5 g of (S)-N-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl-methyl amine (Purity by HPLC: 99.1%).
Example 4
Preparation of N-[3-Phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4- morpholinyl)phenyl]-carbamic acid ethyl ester
Step-1: N-[3-Chloro-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]- carbamic acid ethyl ester
N-Ethyldiisopropyl amine (16.1 g, 0.125 mol) was added to a solution of N-[3-chloro-2- (R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline (28.85 g, 0.1 mol) in methylene chloride (285 ml) at 25-30°C. Ethyl chloroformate (11 g, 0.1 mol) was added to the resulting solution at 25-30°C, followed by stirring the solution at the same temperature for 4 hours. The reaction mass was washed subsequently with 10% hydrochloric acid solution (100 ml), water (100 ml) and saturated brine solution (100 ml) and then concentrated the resulting mass under reduced pressure to produce 35 g of N-[3-chloro-2-(R)- hydroxypropyl]-N- [3 -fluoro-4-(4-morpholinyl)phenyl] -carbamic acid ethyl ester as an oily residue (Yield: 97.2%).
Mass (m/z): 361 (M+l).
Step-2: N-[3-Phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)
phenyl] -carbamic acid ethyl ester
Potassium phthalimide (21.5 g, 0.116 mol) was added to a solution of N-[3-chloro-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester (35 g, 0.097 mol) in dimethylformamide (87.5 ml) and the resulting suspension was heated to
100-110°C and then maintained for 3 hours at the same temperature. The reaction mass was cooled to room temperature (25-30°C), followed by the addition of water (400 ml) and then stirring the mass for 1 hour. The separated solid was filtered to produce 30 g of N-[3- phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-moφholinyl) phenyl] -carbamic acid ethyl ester as an yellow colored solid (Purity by HPLC: 95.8%).
Example 5
Preparation of N- [3-Phthalimido-2-(R)-hydroxypropyl]-N- [3-fluoro-4-(4- morpholinyl)phenyl]-carbamic acid ethyl ester
Step-1: N-[2(R)-2 -epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline
50% Sodium hydroxide solution (9 g) and water (30 ml) were added to a solution of N-[3- chloro-2-(R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline (28.85 g, 0.1 mol) in methylene chloride (200 ml), followed by stirring the solution for 13 to 14 hours at room temperature (25-30°C). After completion of the reaction, water (100 ml) was added to the reaction mass, followed by separation of the layers. The solvent was distilled off from the resulting organic layer to get 24.6 g of N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4- morpholinyl)aniline as a residue (Yield: 97.6%).
Step-2: N-[2(R)-2,3-epoxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester
N-Ethyldiisopropyl amine (15.6 g, 0.12 mol) was added to a solution of N-[2(R)-2,3- epoxypropyl]-3-fluoro-4-(4-mo holinyl)aniline (24.6 g, 0.097 mol) in methylene chloride (250 ml) at 25-30°C. Ethyl chloroformate (11 g, 0.1 mol) was added to the resulting solution at 25-30°C, followed by stirring the solution at the same temperature for 2 hours. The reaction mass was washed subsequently with water (100 ml) and saturated brine solution (100 ml x 2) and then evaporated the solvent to produce 27.9 g of N-[2(R)-2,3- epoxypropyl]-N- [3 -fluoro-4-(4-morpholinyl)phenyl] -carbamic acid ethyl ester (Yield: 88.8%).
Mass (m/z): 325 (M+l).
Step-3: N-[3-Phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4-morphoIinyI) phenyl] -carbamic acid ethyl ester
Potassium phthalimide (18.5 g, 0.1 mol) was added to a solution of N-[2(R)-2,3- epoxypropyl]-N- [3 -fluoro-4-(4-morpholinyl)phenyl] -carbamic acid ethyl ester (27.9 g, 0.086 mol) in dimethylformamide (80 ml) and the resulting suspension was heated to 90- 95°C, followed by maintaining the resulting mass for 3 hours at the same temperature. The reaction mass was cooled to room temperature (25-30°C), followed by the addition of water (400 ml) and then stirring the mass for 1 hour. The separated solid was filtered and then washed with water (50 ml) to produce 28.2 g of N-[3-phthalimido-2-(R)- hydroxypropyl]-N-[3-fluoro-4-(4-morpholinyl)phenyl]-carbamic acid ethyl ester as a cream-yellow colored solid (Purity by HPLC: 95.5%).
All ranges disclosed herein are inclusive and combinable. While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims.
Claims
1. A process for the preparation of Linezolid of formula I:
which comprises:
a) acetylating (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is .Ci-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl;
with an acetylating agent, optionally in the presence of a base, to produce an (R)- phthalimido-2-acetyloxypropyl-carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is as defined in formula IV, and 'Ac' represents an acetyl group; and
b) reacting the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III with a suitable reagent, optionally in the presence of a base, to produce the Linezolid of formula I.
The process of claim 1, wherein the radical Ri in the compounds of formulae III and IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; wherein the acetylating agent used in step-(a) is acetyl chloride, acetyl bromide, acetyl iodide, acetic anhydride, sodium acetate, or a combination thereof; and wherein the reagent used in step-(b) is a primary amine formation agent.
The process of claim 2, wherein the radical R\ is methyl, ethyl, benzyl or tert-butyl; wherein the acetylating agent used in step-(a) is acetic anhydride; and wherein the primary amine formation agent used in step-(b) is hydrazine hydrate or aqueous methyl amine.
The process of claim 1 , wherein the reaction in step-(a) is carried out in the presence or absence of a solvent; wherein the acetylation in step-(a) is optionally carried out in the presence of a base; wherein the reaction in step-(b) is carried out in the presence of a base; and wherein the reaction in step-(b) is carried out in the presence of a second solvent.
The process of claim 4, wherein the reaction in step-(a) is optionally carried out in the presence of a first solvent selected from the group consisting of water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof; wherein the base used in step-
(a) or step-(b) is, each independently, selected from the group consisting of aqueous ammonia, potassium phosphate, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide, potassium tert-butoxide, collidine, trimethylamine, triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, 1-alkylimidazole and 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU); and wherein the second solvent used in step-
(b) is selected from the group consisting of water, an alcohol, a hydrocarbon solvent,
an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
The process of claim 5, wherein the first solvent used in step-(a) is selected from the group consisting of methanol, ethanol, isopropanol, and mixtures thereof; wherein the base used in step-(a) is sodium hydroxide or potassium hydroxide; wherein the base used in step-(b) is potassium carbonate; and wherein the second solvent used in step- (b) is selected from the group consisting of methanol, ethanol, isopropanol, acetone, and mixtures thereof.
A process for the preparation of Linezolid of formula I, or an enantiomeric form or a mixture of enantiomeric forms thereof, comprising reacting the (R)-phthalimido-2- acetyloxypropyl-carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group;
with a suitable reagent, optionally in the presence of a base, to produce the Linezolid of formula I.
The process of claim 7, wherein the radical R\ in the compounds of formula III is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the reagent is hydrazine hydrate or aqueous methyl amine.
A process for the preparation of (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is d-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group;
comprising acetylating (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is as defined above; with an acetylating agent optionally in the presence of a base to produce an (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III or an enantiomeric form or a mixture of enantiomeric forms thereof.
10. The process of claim 9, wherein the radical Ri in the compounds of formulae III & IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the acetylating agent is acetyl chloride, acetyl bromide, acetyl iodide, acetic anhydride, sodium acetate, or. a combination thereof.
11. A process for the preparation of Linezolid of formula I, or an enantiomeric form or a mixture of enantiomeric forms thereof, which comprises:
a) reacting (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein
is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; with a suitable reagent,
optionally in the presence of a base, to produce (S)-N-[3-fluoro-4-(4- morpholinyl)phenyl]-2-oxo-5-oxazolidinyl-methyl amine of formula II:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; and
b) acetylating the amine compound of formula II with a suitable acetylating agent to produce the Linezolid of formula I.
12. The process of claim 1 1 , wherein the radical R\ in the compounds of formula IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; wherein the reagent used in step-(a) is a primary amine formation agent; and wherein the acetylating agent used in step-(b) is acetyl chloride, acetyl bromide, acetyl iodide, acetic anhydride, sodium acetate, or a combination thereof.
13. The process of claim 12, wherein the radical R\ in the compounds of formula IV is methyl, ethyl, benzyl or tert-butyl; and wherein the reagent used in step-(a) is hydrazine hydrate or aqueous methyl amine.
14. The process of claim 11, wherein the reaction in step-(a) is carried out in the presence of a base, wherein the base is an organic or inorganic base; and wherein the reaction in step-(a) is carried out in the presence of a solvent selected from the group consisting of water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
15. The process of claim 14, wherein the base used in step-(a) is selected from the group consisting of aqueous ammonia, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide and potassium tert-butoxide; and wherein the solvent used in step-(a) is selected from the group consisting of methanol, ethanol, isopropanol, acetone, and mixtures thereof.
. A process for the preparation of (S)-N-[3-fluoro-4-(4-morpholinyl)phenyl]-2- oxazolidinyl-methyl amine of formula II:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; comprising reacting (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is Ci-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; with a suitable reagent, optionally in the presence of a base, to produce the aminomethyl compound of formula II, or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
17. The process of claim 16, wherein the radical R\ in the compounds of formulae IV is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the reagent is hydrazine hydrate or aqueous methyl amine.
18. A process for the preparation of (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is Ci-i2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; comprising reacting N-[3-phthalimido-2- (R)-hydroxypropyl]-3-fluoro-4-(4-moφholinyl)aniline of formula XIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XI Vb:
(or)
wherein the radical Ri is as defined in Formula IV; to produce the (R)-phthalimido-2- hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
19. The process of claim 18, wherein the radical R\ in the compounds of formulae IV, XlVa & XIVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; wherein the reaction between the compounds of formula XIII and the activating agent is carried out in the presence of a base, wherein the base is an organic or inorganic base; and wherein the reaction is carried out in the presence of a solvent.
20. The process of claim 19, wherein the radical Ri is methyl, ethyl, benzyl or tert-butyl; wherein the base is an organic base selected from the group consisting of collidine, trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-
methylmorpholine and 1 -alkylimidazole; and wherein the solvent is selected from the group consisting of water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
21. The process of claim 20, wherein the base is diisopropylethylamine; and wherein the solvent is dichloromethane.
22. A process for the preparation of (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is C1.12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; which comprises:
a) reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3- epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group selected from a halogen or a sulfonyloxy group;
with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XI Vb:
wherein the radical Ri is as defined in Formula IV; to produce an (R)-2- hydroxypropyl-carbamate compound of formula VII or an (R)-2,3-epoxypropyl- carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ and Y are as defined above; and
b) reacting the (R)-2-hydroxypropyl-carbamate compound of formula VII or the (R)- 2,3-epoxypropyl-carbamate compound of formula IX obtained in step-(a) with potassium phthalimide, optionally in the presence of a base, to produce the (R)- phthalimido-2-hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
23. The process of claim 22, wherein the radical Ri in the compounds of formulae IV, VII, IX, XlVa & XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-
methoxybenzyl; and wherein the leaving group Y in the compounds of formulae VII and XV is a halogen, or an alkyl or aryl sulfonyloxy group.
24. The process of claim 23, wherein the radical Rt is methyl, ethyl, benzyl or tert-butyl; and wherein the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group.
25. The process of claim 24, wherein the leaving group is CI.
26. The process of claim 22, wherein the reaction in step-(a) and step-(b) is, optionally, carried out in the presence of a base, wherein the base is an organic or inorganic base; and wherein the reaction in step-(a) and step-(b) is, each independently, carried out in the presence of a solvent selected from the group consisting of water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
27. The process of claim 26, wherein the base used in step-(a) is an organic base selected from the group consisting of collidine, trimethylamine, tributylamine, triethylamine, diisopropylethylamine, N-methylmorpholine, and 1-alkylimidazole; wherein the solvent used in step-(a) is dichloromethane; and wherein the solvent used in step-(b) is selected from the group consisting of acetonitrile, Ν,Ν-dimethylformamide, and mixtures thereof.
28. A process for the preparation of (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Rj is Ci-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; comprising reacting the (R)-2- hydroxypropyl-carbamate compound of formula VII or the (R)-2,3-epoxypropyl- carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R] is as defined in Formula IV, and Y is a leaving group selected from a halogen or a sulfonyloxy group; with potassium phthalimide, optionally in the presence of a base, to produce the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
29. The process of claim 28, wherein the radical Ri in the compounds of formulae IV, VII & IX is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifiuoromethanesulfonyloxy group.
30. The process of claim 29, wherein the radical Ri is methyl, ethyl, benzyl or tert-butyl; and wherein leaving group Y is CI.
31. A process for the preparation of (R)-2-hydroxypropyl-carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate compound of formula IX:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl, and Y is a leaving group selected from a halogen or a sulfonyloxy group; comprising reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4- morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group selected from a halogen or a sulfonyloxy group;
with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XlVa, or a chloroformate compound of formula XI Vb:
(or)
wherein the radical R\ is as defined above; to produce the (R)-2-hydroxypropyl- carbamate compound of formula VII or the (R)-2,3-epoxypropyl-carbamate compound of formula IX or an enantiomeric form or a mixture of enantiomeric forms thereof.
32. The process of claim 31, wherein the radical Ri in the compounds of formulae VII, IX, XlVa & XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl,
phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group.
33. The process of claim 32, wherein the radical Rr is methyl, ethyl, benzyl or tert-butyl; and wherein the leaving group Y is CI.
34. A process for the preparation of (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; which comprises:
a) reacting a (R)-2-hydroxypropyl-aniline compound of formula XV or N-[2(R)-2,3- epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group selected from a halogen or a sulfonyloxy group; with potassium phthalimide, optionally in the presence of a base, to produce N- [3 -phthalimido-2-(R)-hydroxypropyl] -3 -fluoro-4-(4-morpholinyl)aniline of formula XIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; and
b) reacting the N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4- morpholinyl)aniline of formula XIII or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; with a suitable activating agent, optionally in the presence of a base, wherein the activating agent is a carbonate compound of formula XI Va, or a chloroformate compound of formula XI Vb:
(or)
XlVb
R,O X O
a wherein the radical Ri is as defined in Formula IV; to produce the (R)-phthalimido- 2-hydroxypropyl-carbamate compound of formula IV or an enantiomeric form or a mixture of enantiomeric forms thereof.
35. The process of claim 34, wherein the radical Ri in the compounds of formulae IV, XlVa & XlVb is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the leaving group Y in the compound of formula XV is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group.
36. The process of claim 35, wherein the radical R] is methyl, ethyl, benzyl or tert-butyl; and wherein the leaving group Y is CI.
37. The process of claim 34, wherein the base used in step-(a) or step-(b) is an organic or inorganic base, each independently, selected from the group consisting of aqueous ammonia, potassium phosphate, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide, potassium tert-butoxide, collidine, trimethylamine, triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, 1-alkylimidazole and 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU); and wherein the reaction in step-(a) and step- (b) is carried out in the presence of a solvent selected, each independently, from the group consisting of water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
38. The process of claim 37, wherein the solvent used in step-(a) is selected from acetonitrile, N,N-dimethylformamide, and mixtures thereof; wherein the base used in step-(b) is diisopropylethylamine; and wherein the solvent used in step-(b) is dichloromethane.
39. A process for the preparation of N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4- (4-morpholinyl)aniline of formula XIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; comprising reacting N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, with potassium phthalimide, optionally in the presence of a base, to produce N-[3- phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula XIII or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
40. A process for the preparation of N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4- morpholinyl)aniline of formula X:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof; comprising reacting (R)-2-hydroxypropyl-aniline compound of formula XV:
or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof, wherein Y is a leaving group selected from a halogen or a sulfonyloxy group; with a base to produce the N-[2(R)-2,3-epoxypropyl]-3-f uoro-4-(4-morpholinyl)aniline of formula X or an enantiomeric form or a mixture of enantiomeric forms thereof, or a salt thereof.
41. The process of claim 40, wherein the leaving group Y in the compound of formula XV is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group; wherein the base is an organic or inorganic base; and wherein the reaction is carried out in the presence of a solvent selected from the group consisting of water, an alcohol, a hydrocarbon solvent, an ester, a ketone, an ether, a nitrile, a polar aprotic solvent, a halogenated hydrocarbon solvent, and mixtures thereof.
42. The process of claim 41, wherein the leaving group Y is CI; wherein the base is selected from the group consisting of aqueous ammonia, potassium phosphate, sodium hydroxide, calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium tert-butoxide, sodium isopropoxide, potassium tert-butoxide, or a combination thereof; and wherein the solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, n-butanol, ethyl acetate, methyl acetate, isopropyl acetate, tert- butyl methyl acetate, ethyl formate, acetone, n-pentane, n-hexane, n-heptane, cyclohexane, toluene, xylene, tetrahydrofuran, 2-methyl-tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, methyl tert-butyl ether, monoglyme, diglyme, acetonitrile, propionitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, dichloromethane, dichloroethane, and mixtures thereof.
43. The process of claim 42, wherein the base is selected from potassium carbonate, sodium hydroxide and potassium hydroxide; and wherein the solvent is selected from water, dichloromethane, and mixture thereof.
44. A (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III:
45. The compound of claim 44, wherein the radical Ri is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl.
46. The compound of claim 44, wherein the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III is N-[3-phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4- (4-morpholinyl) phenyl] -carbamic acid ethyl ester of formula Ilia (formula III, wherein Ri is ethyl):
or an enantiomeric form or a mixture of enantiomeric forms thereof.
47. The compound of claim 44, wherein the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III is N-[3-phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4- (4-morpholinyl) phenyl] -carbamic acid tert-butyl ester of formula Illb (formula III, wherein R1 is tert-butyl):
48. The compound of claim 44, wherein the (R)-phthalimido-2-acetyloxypropyl-carbamate compound of formula III is N-[3-phthalimido-2-(R)-acetyloxypropyl]-N-[3-fluoro-4- (4-morpholinyl) phenyl] -carbamic acid benzyl ester of formula IIIc (formula III, wherein Ri is benzyl):
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein R\ is Ci-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl.
50. The compound of claim 49, wherein the radical R\ is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl.
51. The compound of claim 49, wherein the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV is N-[3-phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4- morpholinyl)phenyl]-carbamic acid ethyl ester of formula IVa (formula IV, wherein R\ is ethyl):
52. The compound of claim 49, wherein the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV is N-[3-phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4- morpholinyl)phenyl]-carbamic acid tert-butyl ester of formula IVb (formula IV, wherein R\ is tert-butyl):
53. The compound of claim 49, wherein the (R)-phthalimido-2-hydroxypropyl-carbamate compound of formula IV is N-[3-phthalimido-2-(R)-hydroxypropyl]-N-[3-fluoro-4-(4- morpholinyl)phenyl]-carbamic acid benzyl ester of formula IVc (formula IV, wherein R\ is benzyl):
54. A (R)-amino-2-acetyloxypropyl-carbamate compound of formula V:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is CM2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and 'Ac' represents an acetyl group.
55. The compound of claim 54, wherein the radical Ri is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl.
56. A (R)-amino-2-hydroxypropyl-carbamate compound of formula VI:
57. The compound of claim 56, wherein the radical Ri is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl.
58. A (R)-2-hydroxypropyl-carbamate compound of formula VII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is C1-12 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; and Y is a leaving group selected from a halogen or a sulfonyloxy group.
59. The compound of claim 58, wherein the radical Ri is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group.
60. A (R)-2-acetyloxypropyl-carbamate compound of formula VIII:
or an enantiomeric form or a mixture of enantiomeric forms thereof, wherein Ri is CM2 straight or branched chain alkyl, cycloalkyl, haloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl; Y is a leaving group selected from a halogen or a sulfonyloxy group, and 'Ac' represents an acetyl group.
61. The compound of claim 60, wherein the radical R\ is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl; and wherein the leaving group Y is selected from the group consisting of CI, Br, I, methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy group.
62. A (R)-2,3-epoxypropyl-carbamate compound of formula IX:
63. The compound of claim 62, wherein the radical Ri is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl.
64. A N-[2(R)-2,3-epoxypropyl]-3-fluoro-4-(4-morpholinyl)aniline of formula X:
65. A (R)-acetamido-2-hydroxypropyl-carbamate compound of formula XI:
66. The compound of claim 65, wherein the radical R is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl.
67. A (R)-acetamido-2-acetyloxypropyl-carbamate compound of formula XII:
68. The compound of claim 67, wherein the radical Ri is methyl, ethyl, propyl, isopropyl, isobutyl, tert-butyl, chloromethyl, phenyl, tolyl, benzyl, p-nitrobenzyl, dibromophenyl or p-methoxybenzyl.
69. Use of the compounds of formulae III, IV, V, VI, VII, VIII, IX, X, XI and XII as claimed in claims 44 to 68, in the process for manufacture of linezolid.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2013/000278 WO2014174522A1 (en) | 2013-04-25 | 2013-04-25 | Improved processes for the preparation of linezolid using novel intermediates |
US14/785,960 US9586913B2 (en) | 2013-04-25 | 2013-04-25 | Processes for the preparation of linezolid using novel intermediates |
EP13883336.3A EP2989097A4 (en) | 2013-04-25 | 2013-04-25 | Improved processes for the preparation of linezolid using novel intermediates |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2013/000278 WO2014174522A1 (en) | 2013-04-25 | 2013-04-25 | Improved processes for the preparation of linezolid using novel intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014174522A1 true WO2014174522A1 (en) | 2014-10-30 |
Family
ID=51791155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2013/000278 WO2014174522A1 (en) | 2013-04-25 | 2013-04-25 | Improved processes for the preparation of linezolid using novel intermediates |
Country Status (3)
Country | Link |
---|---|
US (1) | US9586913B2 (en) |
EP (1) | EP2989097A4 (en) |
WO (1) | WO2014174522A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016079757A3 (en) * | 2014-11-19 | 2018-12-27 | Symed Labs Limited | Novel processes for preparing 5-hydroxymethyl-oxazolidin-2-one derivatives |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060247435A1 (en) * | 2004-07-20 | 2006-11-02 | Dodda Mohan Rao | Novel intermediates for linezolid and related compounds |
US7291614B2 (en) * | 2005-02-24 | 2007-11-06 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of linezolid intermediate |
US20090156806A1 (en) * | 2007-12-18 | 2009-06-18 | Dipharma Francis S.R.I. | Process for the Preparation of Oxazolidinone Derivatives |
US20110034465A1 (en) * | 2009-04-28 | 2011-02-10 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
US20110275805A1 (en) * | 2009-01-13 | 2011-11-10 | Lianhe Chemical Technology Co., Ltd. | Method for preparing linezolid and intermediates thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012051692A1 (en) * | 2010-10-18 | 2012-04-26 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
WO2014141067A2 (en) * | 2013-03-14 | 2014-09-18 | Benova Labs Pvt Limited | Process for the preparation of oxazolidinone derivatives |
-
2013
- 2013-04-25 US US14/785,960 patent/US9586913B2/en active Active
- 2013-04-25 EP EP13883336.3A patent/EP2989097A4/en not_active Withdrawn
- 2013-04-25 WO PCT/IN2013/000278 patent/WO2014174522A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060247435A1 (en) * | 2004-07-20 | 2006-11-02 | Dodda Mohan Rao | Novel intermediates for linezolid and related compounds |
US7291614B2 (en) * | 2005-02-24 | 2007-11-06 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of linezolid intermediate |
US20090156806A1 (en) * | 2007-12-18 | 2009-06-18 | Dipharma Francis S.R.I. | Process for the Preparation of Oxazolidinone Derivatives |
US20110275805A1 (en) * | 2009-01-13 | 2011-11-10 | Lianhe Chemical Technology Co., Ltd. | Method for preparing linezolid and intermediates thereof |
US20110034465A1 (en) * | 2009-04-28 | 2011-02-10 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP2989097A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016079757A3 (en) * | 2014-11-19 | 2018-12-27 | Symed Labs Limited | Novel processes for preparing 5-hydroxymethyl-oxazolidin-2-one derivatives |
Also Published As
Publication number | Publication date |
---|---|
EP2989097A4 (en) | 2017-11-08 |
US9586913B2 (en) | 2017-03-07 |
EP2989097A1 (en) | 2016-03-02 |
US20160102064A1 (en) | 2016-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2902386B1 (en) | A crystalline form of linezolid | |
US6107519A (en) | Process to produce oxazolidinones | |
EP2595968B1 (en) | Novel process for preparation of linezolid and its novel intermediates | |
NZ525923A (en) | Methods of producing oxazolidinone compounds | |
EP2844654A1 (en) | Improved process for preparing rivaroxaban using novel intermediates | |
US9012631B2 (en) | 1,3-oxazolidine-2-one-like compound, preparation method and uses thereof | |
WO2014174522A1 (en) | Improved processes for the preparation of linezolid using novel intermediates | |
WO2014045292A1 (en) | Improved process for the preparation of linezolid intermediate | |
WO2014141067A2 (en) | Process for the preparation of oxazolidinone derivatives | |
CZ293508B6 (en) | Phenyl isoserinate esters of silyl baccatin III | |
WO2016079757A2 (en) | Novel processes for preparing 5-hydroxymethyl-oxazolidin-2-one derivatives | |
USRE47606E1 (en) | Process for the preparation of linezolid | |
US9643939B1 (en) | Process for the preparation of linezolid | |
RU2766082C9 (en) | Improved process of obtaining linezolid | |
WO2013190559A1 (en) | Improved processes for the preparation of linezolid crystalline form iii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13883336 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14785960 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013883336 Country of ref document: EP |